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Abstract 
 
 
Prostate cancer is the second most frequent cause of cancer deaths in men, and the 
risk to develop cancer increases with age. Since the lifespan of the society is 
progressively increasing, the importance of preventing the development of this common 
disease is becoming more urgent. The prevention and therapy options for non-metastatic 
prostate cancer are available but limited. For the androgen-insensitive, metastatic form of 
prostate cancer there still is no effective therapy. 
Our laboratory has an estrogen receptor based perspective on prostate cancer. We 
are using a transgenic mouse as an animal model to study the development and treatment 
of prostate cancer. We are also investigating a selection of botanical compounds that have 
been implicated as cancer protective either by traditional medicine or in modern cancer 
research.  
The TRAMP (TRansgenic Adenocarcinoma of the Mouse Prostate) model 
enables us to study the specific roles of estrogen receptors in prostate cancer progression. 
The expression of the two estrogen receptors alpha (ERα) and beta (ERβ) in TRAMP 
mouse prostates switches upon progression from non-metastatic to metastatic tumor 
phenotype. During earlier stages of cancer, ERβ is the main estrogen receptor present, as 
the phenotype of the cancer changes to the more neuro-endocrine like, the expression of 
ERβ decreases and ERα seems to remain the only active receptor. 
Initial studies in the Lubahn lab and elsewhere led us to hypothesize a protective 
role for ERβ in prostate cancer tumorigenesis. The presence of ERβ only seems to 
prevent or slow down the incidence of (PDC) poorly differentiated carcinoma in contrast 
 xviii
to ERα, which promotes the metastatic, neuro-endocrine like phenotype. We have found 
though a study in double transgenic mice, that were WT and KO for estrogen receptors 
alpha or beta on a TRAMP background, that ERαKO mice did not develop poorly 
differentiated carcinoma (75% reduction compared to control animals), however ERβKO 
mice had significantly increased PDC incidence and had double the PDC compared to 
animals WT for both receptors. 
We were also interested in cancer protective properties of a variety of botanical 
compounds, reported in the literature to be potentially beneficial for prostate health, and 
widely bought through health food stores around the country. We specifically 
investigated apigenin, baicalein, curcumin, EGCG, genistein, quercetin, and resveratrol, 
both in vitro and in vivo. All seven compounds were able to delay prostate cancer cell 
growth of both human (LNCaP, PC3, and PC3M) and mouse (TRAMP-C2) prostate 
cancer cell lines. All seven compounds combinations were also able to inhibit or delay 
prostate cancer incidence by up to 80%, specifically at the well differentiated carcinoma 
stage, when fed to TRAMP mice. The protective effects were only present in ERWT 
mice, indicating a need for both receptors for these compounds to act on the prostate 
cancer incidence. 
I introduced a new pathway to the lab, the hedgehog signaling pathway, which 
has been recently found to play a role in prostate cancer, specifically in metastatic cancer. 
Several botanicals used in the lab were able to inhibit the hedgehog pathway as indicated 
by decreasing Gli1 levels. With IC50 values ranging from <1μM to 25μM these 
compounds demonstrated hedgehog pathway inhibition by deceasing Gli1 mRNA 
concentration by up to 95% and down regulating Gli-reporter activity by 80%. Also, both 
 xix
estrogen and ICI inhibit Gli1 mRNA in TRAMP-C2 cells, and Gli-reporter activity in 
Shh Light II cells.  
My research sheds light on an additional mechanism by which phytoestrogens are 
potentially protecting against cancer. My work suggests a potential new treatment target 
for addressing both slow and fast growing prostate cancers. Based on data presented here, 
we propose that a combination of ERα antagonists, ERβ agonists and selected botanicals 
should present a comprehensive prostate cancer remedy. 
  
 xx
 1 
I - Background 
 
Prostate Cancer 
Prostate cancer, after skin cancer, is the second most common form of cancer in 
men in America. According to the Prostate Cancer Foundation over 186,000 men were 
diagnosed with prostate cancer in 2008, and almost 30,000 men will die from the disease 
(1). After lung cancer, prostate cancer is the leading cause of cancer-related deaths 
among men in the U.S. It is estimated that there are over 2 million American men 
currently living with prostate cancer. The chance of having prostate cancer increases 
rapidly after age 50. More than 70% of all prostate cancers are diagnosed in men over the 
age of 65. It is still unclear why this increased risk with age occurs for prostate cancer 
(2). 
Risk factors for prostate cancer may be found in both genetic and environmental 
areas. While there are no genes so far that have been reported to cause prostate cancer 
(3), but there are some which are correlated with a higher chance of developing the 
disease. Epidemiological studies showed, for example, that a polymorphism in the 
CYP1A1 gene, causing increased activity of the cytochrome P450 enzyme involved in 
the metabolism of estrogens to form reactive catechol estrogens or quinone/semiquinone 
intermediates, like 2-hydroxy-(OH)-estrogens, makes the carriers of this allele have a 
higher incidence of prostate cancer (4). There are also genetic markers correlated with a 
higher prostate cancer risk like HPCX (Hereditary Prostate Cancer X-linked) (5), HPC1 
(Hereditary Prostate Cancer 1) (6), PCaP (Predisposing for Prostate cancer) (6), and other 
predisposition loci (3, 7, 8), but together these genetic factors are found responsible for 
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only 9% of all cancer cases (9, 10). Additional risk factors include environmental factors 
(11), and maybe more importantly for this dissertation, dietary factors (12), to be 
discussed in more detail later in this chapter. 
 
Estrogen Signaling Pathway 
Estrogen receptors are ligand-activated transcription factors that belong to the 
large family of steroid or nuclear receptors together with the receptors for androgen, 
progesterone, glucocorticoid, and a whole range of orphan receptors whose ligands are 
still to be found (13). 
Currently two types of estrogen receptors have been identified, alpha (ERα) 
cloned in 1986 (14-16), and beta (ERβ) cloned a decade later (17). There are three major 
isoforms described for ERα and at least 5 for ERβ (Figure I-1).  
The classic mechanism of action for estrogen receptors was proposed in 1962 by 
Elwood Jensen (18), who used tritiated estradiol to demonstrate the nuclear localization 
of the ER (19).  The classic estrogen, 17β-estradiol, which is synthesized in the ovaries in 
response to hypothalamic-pituitary-gonadal signaling, is circulating in the blood in either 
free form or bound to steroid binding globulins. It can cross the cell membrane and bind 
to cytosolic or nuclear localized estrogen receptor molecules. Bound ER in the nucleus, 
forms homo- or heterodimers, and binds an estrogen response element (ERE) on 
promoters of target genes (Figure I-2). They are able to recruit co-regulators and the 
basal transcription machinery, to initiate or block target gene transcription, to mediate its 
response.  
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Non-genomic responses to estradiol are mediated through a membrane bound 
estrogen receptor, as proposed by Ellis Levin (20), and results in ERK, PI3K, cAMP, and 
eNOS pathway activation, and can cross-talk, i.e. synergize with nuclear responses, by 
activating ER though phosphorylation. In addition, there are other reported proteins that 
can bind and/or respond to estrogens, like the controversial orphan G-coupled receptor 
GPR30 (21). 
Besides the classic estrogen, 17β-estradiol, which is the reference ER “agonist” 
there are a range of estrogen metabolites, botanical compounds with estrogenic properties 
and synthetic estrogen receptor ligands (for structures see Figure I-3). ICI 182,780 or 
fulvestrant is a pure estrogen receptor antagonist, binding both ERs with nanomolar 
affinities and targeting them for degradation (22). In addition to the pure agonist and 
antagonist which are defined both by response relative to 17β-estradiol and the structural 
positioning of the switch-helix 12, selective estrogen receptor modulators (SERMs) (23) 
elicit their action in a tissue- and promoter dependent manner (Figure I-3) (24). 
 
Estrogen Receptor Mouse Models 
The ERαKO mouse was generated by my adviser, Dr. Dennis Lubahn using 
homologous recombination in mouse embryonic stem cells to disrupt the ERα gene (25, 
26). We have established large breeder colonies of these animals. Estrogen insensitivity is 
evident in these mice, however male and female sexual differentiation and development 
occurs (26). The recently cloned ERβ has been found in the ERαKO mice prostate and 
other tissues (27-29). Other non-ERα, non-ERβ estrogen-response proteins have not been 
fully characterized but may mediate specific effects of estrogens in cells (30, 31). We 
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also have established colonies of ERβKO mice generated by similar techniques (32). 
These mice are fertile, although females have smaller litters (33), the males however, 
show no overt phenotype as accepted by most, but not all. Jan Ǻke Gustafsson reports a 
range of abnormalities in ERβKO mice including hyperplastic prostate (34), as well as 
impaired hearing (35, 36), brain development (37), and social behavior (38). We further 
developed a double transgenic mouse model with ERαKO or ERβKO mice on the 
TRAMP (TRansgenic Adenocarcinoma of the Mouse Prostate, described later in this 
chapter) (39) background to elucidate the contributions of each receptor to prostate 
cancer incidence as well as study mechanisms of action of potential estrogenic 
compounds.  
 
Estrogens and Breast Cancer 
 Breast cancer, which is the oldest form of cancer described, dating back 1600 BC 
(40), is another hormone cancer, and shares some parallels with prostate cancer.  
Elwood Jensen was a pioneer in distinguishing between patients with ER-positive 
and ER-negative tumors, and thus predicting which patients are likely to respond to 
estrogen ablation therapy, and which should rather receive more aggressive radio- and 
chemotherapy (41).  
For ER-positive breast cancer, the two hormones of choice were raloxifen and 
tamoxifen, which have also been proposed to be used in a preventative regimen for 
postmenopausal women with increased risk for developing breast cancer (42).  
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Estrogens and Prostate Cancer 
Chemical castration that removed androgens through the use of estrogens was 
first described by Charles B. Huggins in 1941 (43), and his work was honored in 1966 
with a Nobel Prize. Andrzej W. Schally and Roger Guillemin subsequently described the 
role of Gonadotropin-Releasing Hormone in reproduction, and were honored by the 
Nobel Prize in 1977. Their work lead to the development of GnRH receptor agonists such 
as leuroprolide and goserelin for prostate cancer treatment which block testosterone 
synthesis (44, 45). 
Estrogen therapy, principally the use of a nonsteroidal estrogen diethylstilbestrol 
(DES), was a suggested practice in earlier days for prostate tumor treatment (46-48). Its 
primary mode of action is through feedback on the anterior pituitary with suppression of 
gonadotropin secretion and subsequent decrease in testosterone production by Leydig 
cells of the testis. This would in turn cause a decrease in androgens required for hormone 
dependent cancer (49). However, direct effects of DES through ER are also possible, 
since both estrogen receptors are expressed in the prostate. It has not been fully 
determined whether DES works through a classical ERα pathway, through ERβ or 
another estrogen-dependent mechanism.  
Due to the increased risk of dying from heart disease or stroke after DES 
treatment, it is no longer used in therapy (50, 51). The main reason however, to ban the 
use of DES was its detrimental effect on children whose mothers were using the widely 
prescribed drug to prevent miscarriage during pregnancy (52). 
Transdermal estradiol introduced by means of patches has been reported to reduce 
testosterone levels after 3 weeks of treatment with an average 95 percent reduction in 
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PSA, without the cardiovascular toxicity observed up to 14 months after treatment (53, 
54). 
Other synthetic estrogens, like conjugated estrogens (Premarin), ethinyl estradiol 
(Estinyl), medroxyprogesterone acetate (Provera), chlorotrianisene (TACE), have been 
tested for their potency in suppressing the production of luteinizing hormone and thus 
lower the testosterone production. All, except TACE, were able to lower LH production, 
but unfortunately they also resulted in significant cardiovascular toxicity, and were not an 
acceptable alternative to DES (55). 
The actions mediated by the estrogen receptors α and β in the prostate seem to be 
of opposite character (56-58). In the rodent prostate, ERβ has been reported to be present 
in the epithelial cells throughout the normal organ. It has been also reported to be 
expressed in prostate cancer metastases (59). ERα on the other hand is expressed at low 
levels in the stromal cells with decreasing levels across the specific lobes from lateral to 
dorsal to ventral (60), but not in the epithelium. Ricke et al. recently proposed that in situ 
estrogen production is contributing to carcinogenesis of the prostate, since aromatase KO 
mice did not develop tumors in the described testosterone+estradiol induced prostate 
cancer model (61). ERα is also proposed to be necessary for prostate cancer development, 
since mice lacking the alpha receptor did not develop cancers (62). 
In BPH, benign prostatic hyperplasia, the levels of ERα have been reported to 
increase compared to normal prostate (63). 
The expression of both estrogen receptors seen in our mouse model undergoes a 
transition during prostate cancer progression. TRAMP mice with prostatic hyperplasia 
(score 2, non-cancer) do not express ERα but have detectable ERβ. Once the tumor 
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progresses through the poorly differentiated carcinoma stage (score 6), ERβ expression is 
absent in most cells and the major receptor present remains ERα (unpublished data, Dr. 
Besch-Williford).  
 
Stromal - epithelial cell communication in the prostate 
There is a significant amount of paracrine signaling between the stromal cells and 
the epithelial cells in the prostate, critical for both development and tumorigenesis. Even 
though prostate cancer is primarily arising in the epithelial cells of the prostate, Cunha et 
al. propose the prostate stroma to be the determining factor in benign vs. malignant 
growth of the prostate (64). Abnormal stromal cells derived from a human carcinoma 
stimulated epithelial proliferation and induced carcinoma when combined with benign 
epithelium (65). Studies with recombinant prostate tissues containing androgen receptor 
(AR) positive and negative mesenchyme and epithelium demonstrated that even though 
the androgen responsive cells are present in the epithelium, there is no requirement for an 
epithelial androgen receptor. An AR- mesenchyme combined with AR+ epithelium will 
not respond to androgens, and thus fail to develop properly (66). Hedgehog signaling, to 
be described later, provides a mechanism for paracrine stromal cell to epithelial cell (and 
vice versa) communication. 
 
Androgens in the prostate  
The development and growth of the prostate gland is dependent on the presence 
of androgens. An observation by the Scottish surgeon John Hunter in 1786 that castrated 
bulls had small prostates, led to the treatment of prostate cancer by castration in the next 
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century. Prostate cancer was first described in 1853 (67), and first reports of castrations 
came from Hugh H. Young at Johns Hopkins Hospital in 1904  (68-71).  
The main androgen, testosterone is synthesized by the Leydig cells in the testis 
and by the adrenal gland. In the prostate, testosterone is metabolized by 5α-reductase to 
the more potent 5α-dihydrotestosterone (DHT), which binds to the androgen receptor 
(AR) to induce AR’s transcriptional activity. Androgen ablation and blockage of the AR 
are used to halt androgen responsive prostate cancers. At first this blocks proliferation in 
the epithelial cells but eventually, the cancer escapes the androgen-dependency, and 
spreads. The prostatic stroma also expresses AR, but is not dependent on androgens. 
After androgen withdrawal, the AR expression in the stroma is lost, but there is no effect 
on stromal growth (72, 73).   
The suggested neoadjuvant hormonal therapy for prostate cancer today combines 
a luteinizing hormone releasing hormone (LHRH) agonist combined with radiation 
therapy for 24 months, or a combination of LHRH agonist plus antiandrogen for six 
months (74). 
Recently, intratumoral de-novo synthesis of testosterone within the prostate has 
been proposed as one mechanism (75), by which androgen-deprived tumors maintain 
androgen-related gene expression in the prostate (76) in the absence of exogenous 
androgens. 
 
Anatomy of the prostate 
The diverse phenotypes of prostate cancer cells can be seen in human prostate 
cancer patients. The most common, slow growing cancers arise in the epithelium. The 
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basic cell types making up the prostatic epithelium are the secretory luminal cells, basal 
cells, and endocrine cells. Currently the androgen sensitive luminal cells are seen as the 
origin of common adenocarcinoma (77). The majority of the tumor mass consists of 
exocrine cells, which are closely related to the secretory cell type within the transitional 
zone of the prostate epithelium. But about 10% of all human adenocarcinomas of the 
prostate have extensive multifocal neuroendocrine differentiation present (78). The 
neuroendocrine cells themselves are androgen insensitive, do not proliferate, and reside 
in a quiescent G0 state, which makes the resistant to many therapeutic procedures. They 
produce detectable serum markers like Chromogranin A, B, and C, but also growth 
factors that can stimulate the proliferation of adjacent tumor cells (78).   
 
The human prostate gland consists of three distinct anatomical zones, the 
transitional, central and peripheral zones, and each contains several distinct epithelial cell 
systems, the basal, secretory luminal and endocrine cells (77). Secretory luminal cells 
express the androgen receptor (AR), and require continuous support by circulating 
androgens. Basal cells are androgen independent, but a small basal cell population 
expressess the androgen receptor and remains androgen responsive (79). The maturation 
process of basal cell into luminal cells is induced by androgens, and counterbalances 
estrogen-induced basal cell hyperplasia. In the normal prostate 70% of proliferating 
epithelial cells express basal cell-specific cytokeratins, and the remaining 30% of cycling 
cells are found in the secretory epithelium (80). Neuroendocrine cells lack proliferative 
activity and represent a post-mitotic, terminally differentiated cell population (81). 
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The mouse prostate is divided into four distinct lobes: the ventral prostate, the 
dorsal prostate, the lateral prostate and the anterior prostate (coagulating gland) (82). 
These lobes function independetly to supply protein to the seminal fluid, with the 
anterior, dorsal and lateral prostate having a similar secretory profile, while the proteins 
secreted by the ventral prostate are quite distinct (83). The dorsolateral prostate of the 
mouse can be compared with the human peripheral zone as far as the origins of PIN 
(prostatic intraepithelial neoplasia) are concerned (84). Benign prostatic hyperplasia 
originates usually in the periurethral, transitional zone in human (85).  
 
TRAMP Mouse Model 
The animal model used in our lab is known as TRAMP for TRansgenic 
Adenocarcinoma of the Mouse Prostate, and was developed by placing the SV40 large 
and small T-antigen genes under the control of the rat probasin promoter. Probasin has 
been shown to be highly and specifically expressed in prostate (86). The transgene known 
as PBTag, is highly expressed throughout the prostate. This oncoprotein is known to 
abrogate tumor suppressor functions of p53 and Retinoblastoma (Rb) and thereby drive 
the cell through the normal cell cycle checkpoints. In our hands ~60-85% of ER wild type 
/TRAMP mice develop prostate cancer spontaneously within 5 months. The strength of 
the TRAMP model is that tumorigenesis can be studied from normal through metastatic 
cancer (http://thegreenberglab.fhcrc.org) so that prevention studies can be performed, 
unlike common human cancer xenograft models in mice, which are useful models for 
prostate cancer therapy but not prevention (Figure I-4). We finished our studies at five 
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months so we can observe a range of different tumor stages and can detect nuanced 
changes resulting from the various dietary treatments (Figure I-5) (87).  
To study the TRAMP model in vitro, we are using the TRAMP-C2 prostate tumor 
cell line (CRL-2731). The cell line was derived in 1996 from a heterogeneous 32 week 
primary tumor in the prostate of a PB-Tag C57BL/6 (TRAMP) mouse (88). The cells 
were reported not to express the Tag antigen (SV40 T), but I was able to detect large and 
small Tag mRNA by RT-PCR. According to ATCC’s specification the cells express the 
Androgen Receptor (AR). They also express both estrogen receptors ERα and ERβ as 
was determined in our lab by RT-PCR (Figure IV-1). 
 
Poorly Differentiated (“Neuroendocrine like”) Carcinoma (PDC) in TRAMP mice 
In our TRAMP studies, we have found that PDC arises predominately in the 
ventral lobe of the prostate, as also reported by Paula and Greenberg, 2003 (89). The 
PDC we observe is characterized by being heterogeneous for positive staining with 
synaptophysin and starts as a focus of neuroendocrine cell proliferation, then 
progressively penetrates the tubules, and proliferates in the stroma, encroaching on 
adjacent tubules and eventually surrounding the urethra (See progression in Figure I-4 A 
to D). The incidence of PDC has been reported to increase with androgen ablation (90, 
91). In our TRAMP studies, the incidence of well differentiated carcinoma (WDC) was 
predominantly found in the dorsal lateral prostate and in the ERαKO casein group was 
significantly (P< 0.00001) higher compared to ER  WT casein. On the other hand, the 
ERαKO casein group has a significantly (p<0.0006) lower frequency of PDC compared 
to ER  WT casein (Table II-1). However, the incidence of PDC was higher in ER KO 
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than in ER WT casein. One speculation is that ERα and ERβ have opposing roles in the 
prostate in regard to prostate cancer and that ERα facilitates the development of PDC, 
while ERβ plays a protective role in prostate cancer. This role is supported in the 
literature (34, 92, 93). The balance between ERα and ERβ seems to have a significant 
role in the development of PDC. 
 
Cancer Stem Cells 
 The existence of cancer stem cells has been proposed more that 40 years ago, but 
first conclusive evidence for such was not published until 1997 in leukemia (94).  
Stem cells have the capacity to divide endlessly without acquiring mutations due 
to a protective mechanism allowing for parental strand maintenance (95). They also have 
a mechanism to protect the cells from random mutations in the parental DNA strand 
mediated by p53-dependent stem cell apoptosis and G1 arrest by transforming growth 
factor (TGF-β) (96). 
Stem cells are pluripotent and characterized by their ability to produce different 
cell lineages. The cancer stem cell hypothesis proposes two possible mechanisms of 
cancer origin: oncogenic mutations may inactivate the constraints on normal stem cell 
expansion (97) or mutations lead to a continuous proliferating cell pool of more 
differentiated cells, that no longer enter a postmitotic differentiated state and expand 
accumulatig more and more mutations (98). 
Stem/progenitor cells residing in niches in the prostate, growth restricted during 
androgen-responsive growth both in the normal and hyperplastic prostate, could be the 
source of the aggressive non-responsive phenotype that occurs after initial hormonal or 
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surgical treatments. Targeting stem cell niches, the specific microenvironment that 
enables cells to maintain self-renewing properties is a potential secondary treatment 
option (99). The hedgehog signaling pathway has been proposed to play a crucial role in 
human cancer stem cell renewal and tumorigenicity and may be responcible for tumor 
reoccurrences after radiation therapy (100). Suggested therapies targeting cancer stem 
cells would include induction of the stem cell into a more differentiated state or inhibition 
of the self-renewing stem cell state (101). Analogues of the hedgehog inhibitor 
cyclopamine are in phase II human trials for several cancers (16 trials to date on 
clinicaltrials.gov). Hedgehog therapy in pancreatic cancer is being monitored based on its 
property to reduce aldehyde dehydrogenase, a stem/progenitor marker (102). 
 
Botanicals and Cancer 
It has been recognized that a Western high-fat diet is increasing the risk to 
develop prostate cancer (103, 104). Other nutrients have a protective effect against 
prostate cancer, like lycopenes found in tomatoes, which act as antioxidants (105-107) 
and have been correlated with epidemiological significantly decreased prostate cancer 
incidence. On the other hand foods or food supplements rich in calcium are thought to 
cause prostate cancer (108). The soy isoflavones daidzein and genistein are also believed 
to reduce prostate cancer risk (109, 110). We have selected seven botanical compounds 
that have been implicated to have cancer protective properties. These compounds have 
been also suggested to have estrogenic and/or antiestrogenic properties, and where thus 
of highest interest to us. These compounds include apigenin, baicalein, curcumin, EGCG, 
genistein, quercetin, and resveratrol (for structures see Figure III-10). A study from our 
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lab has shown all 7 have estrogen binding activity (111). More recently, we have also 
focused our attention on cyclopamine, a compound isolated from corn lily, which can 
inhibit the hedgehog signaling pathway.  
 
Apigenin 
Apigenin is a flavone, found in various flowers and vegetables, among others in 
chamomile.  Apigenin itself, or extracts from its plants of origin have been used in 
prostate cancer research in vivo (112-115), and in vitro (111, 116-122). 
Mechanistically, it is proposed to act as a potent inhibitor of CYP2C9 (123), and thus 
affect drug metabolism, inhibitor of CYP1B1 (124), casein kinase 2 (117, 125, 126), 
topoisomerases I and II (127, 128), oncogenic proline-directed protein kinase FA (PDPK 
FA) (129), and 17beta-hydroxysteroid oxidoreductase (130). It is selectively proapoptotic 
(131-134), and inhibits synthesis of the inflammatory mediators nitric oxide and 
prostaglandin E2 (135), reducing inducible nitric oxide synthase (iNOS) and 
cyclooxygenase-2 (COX-2) expression (136). Apigenin induces  HER2/neu degradation 
(137-139). It inhibits HIF-1 alpha and VEGF expression through the Akt pathway (120, 
140), inhibits fatty acid synthase activity (139, 141), and induce glutathione (GSH) 
depletion (142). It has been reported to have estrogenic activity (128, 130, 143, 144) 
acting specifically through ERβ (122) (siRNA against ERβ abrogated apigenin 
antiproliferative effect, but not that of genistein in DU145, and MDA-MB-231) 
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Mechanism of action of novel agents (145) 
 
Baicalein 
Baicalein and baicalin, are the most common flavonoid components of scutellaria 
extracts, and have shown antiproliferative and proapoptotic activities against various 
cancer cells (146-148), specifically prostate cancer (111, 116, 149-153). Baicalein has 
also shown a favorable effect in cisplatin-induced cell death of human glioma cells (154). 
Mechanistically it has been shown to inhibit prostaglandin E2 production (155), 12-
lipoxygenase (156, 157), 5α-reductase (158), and aromatase (CYP19) (159). It has been 
shown to down-regulate MMPs (160), androgen receptor expression (151, 161), and 
decrease tumor volume in vivo (162).  
 
Curcumin 
Curcumin, found in the Indian curry spice tumeric, was first isolated from the 
perennial plant Curcuma longa in 1910 (163).  
It has been reported to degrade androgen receptor (164, 165), and is able to inhibit 
constitutive NFκB activation (165), and lead to inhibition of cancer proliferation and the 
inflammatory biomarker PSA (prostate specific antigen) expression (166). It is 
proapoptotic (111, 167)  through inhibition of PI3K/Akt pathways and upregulation of 
p53 (168). Inhibits MMPs 2 and 9 (169), inhibits tumor growth in vivo (169-171), in the 
TRAMP (172). It can block prostate cell motility and invasion by down-regulating the 
expression and activity of CC motif ligand 2 (CCL2) (173). Curcumin has anti-
inflammatory (174, 175) and chemoprotective properties and has been found to attenuate 
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AhR/ARNT-mediated CYP induction by dioxin (176), inhibit glyoxalase 1 (177). It 
enhanced the activities of Phase 2 detoxification enzymes of xenobotic metabolism, 
including glutathione transferase (178) and NADPH:quinone reductase (179). It also 
inhibited pro-carcinogen activating Phase 1 enzymes such as cytochrome P450 1A1 
(180). Curcumin is a potent antioxidant (181, 182), with a unique conjugated structure 
that includes two phenols and an enol form of a β-diketone, which might give it  a typical 
radical trapping ability and a chain-breaking anti-oxidant activity (183). It has been tested 
as an anti-HIV agent (184, 185). 
Synthetic curcumin analogues are being tested in breast and prostate cancer treatment 
(186, 187). 
 
EGCG 
Epigallocatechin 3-gallate is the most abundant catechin found in green tea. It  
inhibits prostate cancer in vitro (188-191), in vivo (192, 193) models, and has been used 
in clinical trials (194). 
EGCG is proapoptotic (111, 188, 195), inhibits fatty acid synthase activity (141), 
VEGF(194), 5α-reductase (158), AR and PSA expression (196) in prostate cancer cells. It 
regulates cell and mitochondrial membranes, and thus motility and viability, through 
interactions with cellular zinc (189, 197). It is able to inhibit MAP kinases and activator 
protein 1 (AP-1) (198-200), inhibit NFκB activation and nuclear translocation (201). It 
has been reported to inhibit EGFR-mediated pathways (202, 203), among others in 
TRAMP mice (204). EGCG was able to inhibit uPA (205), MMPs 2 and 9 in vitro and in 
vivo. Some of its cancer protective effects have been suggested to be mediated through 
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the 67kDa laminin receptor, which is expressed in a variety of tumor cells, and binds 
EGCG with nanomolar affinities (206). EGCG acts as an anti-oxidant (190), promotes 
translocation of insulin-sensitive glucose transporter (GLUT) 4 into skeletal muscle 
(207). It has been shown to act synergistically with tamoxifen to inhibit growth of ER- 
breast cancer cell lines in vitro (208), and with curcumin in vitro and in vivo (209).  
Several studies on EGCG and HIV have been described, as discussed by Nance & 
Shearer (210), but there is not yet enough evidence for anti-viral properties of green tea. 
 
Genistein 
Epidemiologic studies suggested a lower incidence in prostate cancer among 
Asian men, compared to men in the Western world. A correlation with diet, especially the 
high consumption of soy in the Asian countries has been proposed as the main variable 
(211-213).  
Genistein (4’,5,7-trihydroxyisoflavone) is the main phytoestrogen found in soy 
(214). It has a structure similar to 17β-estradiol, and is a natural ligand for the estrogen 
receptors, with a binding affinity (Ki) of 2.6 nM for ERα and 0.3 nM for ERβ (215). 
Although genistein has a ~30 fold higher affinity for ERβ compared to ERα, it has been 
shown to have a potency only 4-5 times higher when acting through ERβ compared to 
ERα, and although it is a full agonist with ERα, (107-130% of E2 activity on ERE-
luciferase assays), it does display only partial agonist character with ERβ, indicating that 
the ligand might not induce an optimal agonist conformation with ERβ (216).  
Besides having estrogenic character (111), genistein also acts through other 
mechanisms. Some of its non-estrogen receptor mediated cellular responses include 
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potent inhibition of tyrosine kinases (217-219), stabilization of topoisomerase II, and 
transcriptional regulation of transforming growth factor β. Genistein has been reported to 
inhibit tyrosine kinase activity by competing with ATP (220). It can act as a 
phytoestrogen (111, 221), and alter the activity of enzymes involved in steroid 
metabolism: HMG-CoA reductase (222, 223), 5α-reductase (224), 17β-hydroxysteroid 
dehydrogenase (225), aromatase (226), and other P450 pathways (227). There have been 
reports of genistein’s acting as an antioxidant (228, 229), and its ability to alter DNA 
methylation (230, 231). Recently two papers were published, describing the anti-
metastatic effect of genistein (232, 233).  Interestingly, genistein will increase the 
bioavailability of EGCG in vitro and in vivo (234). 
 
Quercetin 
Quercetin is a flavonol found in a variety of plants, among others citrus fruits, 
buckwheat and onions. It can act as an anti-inflammatory agent (235) and anti-oxidant 
(236-238). Quercetin induces Ap1 in PC3 cells (239) and inhibits expression and activity 
of androgen receptor (240, 241) through activation of c-Jun (242). It has been reported to 
inhibit fatty acid synthase activity (141), 5α-reductase (158, 243), ErbB-2 and ErbB-3 
(244), and AKR1C3 (also known as 17beta-hydroxysteroid dehydrogenase type 5 or 
3alpha-hydroxysteroid dehydrogenase type 2) (245), which have been found to be over-
expressed in prostate cancer. Quercetin, and genistein also represent potent non-
competitive inhibitors of sulfotransferase 1A1 (or P-PST) (159). Quercetin has been 
shown to inhibit prostate cancer growth in vitro (246-249) and in vivo (250-252). 
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Interestingly both genistein and quercetin have been shown to activate the mutant 
androgen receptor (T877A) in LNCaP cells (253).  
 
Resveratrol 
Resveratrol has been reported to inhibit prostate cancer in vitro (188, 254-256), 
and in vivo (170, 257-260). It has the ability to down-regulate androgen receptor (242, 
261), at the post-translational level (262) and to bind Glutathione sulfotransferase-pi 
(GSTP1) and estrogen receptor-beta (ER-beta) (263). It inhibits the formation of 
depurinating estrogen-DNA adducts, that are thought to play a role in initiating breast and 
prostate cancer (264). 
It acts proapoptotic (188, 265) though inhibition of PI3K/Akt pathways (266, 267), and 
inhibition of NFκB (268), CK1 (188), and interactions with TRAIL (TNF-related 
apoptosis inducing ligand) (266, 269, 270). It also has the ability to inhibit Src tyrosine 
kinase activity (271) and stimulate prostaglandin release in prostate cancer cells (272). 
Resveratrol has been also reported to act as an antioxidant (238) and anti-inflammatory 
agent in prostate cancer (273). 
 
Cyclopamine 
  In the 1950s several one-eyed lambs were born on an Idaho farm, and it took 
scientists from the Department of Agriculture 11 years to link the birth defects to wild 
corn lilies (Veratrum californicum), on which the pregnant sheep were grazing during 
droughts (274). In 1965 researchers isolated the responsible compound 11-deoxojervine, 
and named it cyclopamine (275). It took another 25 years to link the newly discovered 
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hedgehog signaling pathway to the old teratogen cyclopamine (276). Mutations in Sonic 
Hedgehog resulted in holoprosencephaly in mice (277), and humans (278). Knocking out 
one of the pathway components, the trans-membrane receptor Smoothened resulted in 
one-eyed mice. The phenotype could be copied through in utero cyclopamine exposure 
(279). Beachy et al. demonstrated subsequently that cyclopamine could directly bind and 
thus inhibit Smoothened (280).  
 
Hedgehog Signaling Pathway 
The hedgehog signaling pathway is important in proliferation and developmental 
patterning of many tissues, including the prostate. The pathway works by allowing the 
coordination of epithelial-mesenchymal interactions and subsequent differentiation (281, 
282). 
The pathway takes its name from the activating ligand, a secreted protein – 
hedgehog. In vertebrates there are 3 homologues with tissue specific and overlapping 
expression and function – Indian, Desert, and Sonic Hedgehog. In absence of the ligand, 
the receptor – Patched is constitutively repressing another transmembrane protein – 
Smoothened (Figure I-5). Upon ligand binding, Patched releases Smoothened from its 
inhibited state in the cytosol. Smoothened then can migrate to the tip of the primary 
cilium, where it interacts with the Gli family transcription factors which are activated and 
can now migrate to the nucleus to execute the hedgehog response (283-290) (Figure I-6).  
Sonic hedgehog is synthesized as a 45kDa precursor, which is then cleaved 
autoproteolytically to generate a 19kDa N-terminal signaling peptide (291). During 
cleavage cholesterol is covalently attached to the C-terminus of the peptide to anchor it in 
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the cell membrane (292). A second lipid modification that incorporates palmitic acid 
occurs at the N-terminal cysteine that is exposed after signal peptide cleavage (293). This 
step is catalyzed by the transmembrane acyltransferase Skinny hedgehog
 
(Ski) (294). 
Dispatched (Disp), a 12-pass transmembrane protein is needed to release the hedgehog 
protein from the cell membrane (295). 
The lipid modifications on hedgehog are required to maintain a signaling gradient, 
that results in the proper cell fate and patterning (296). The way the hedgehog ligand 
moves between origin and target cell is still being debated (297). It could form micelle-
like structures with its lipid moieties embedded in the core. It has been proposed that 
lipoprotein particles could carry hedgehogs between cells for long-range transport (297) 
and potentially systemically. The transport of Hh among tissues also requires heparan-
sulfate (298). Perlecan, an extracellular matrix proteoglycan is a recent discovered 
modulator of the sonic hedgehog signaling in prostate cancer (299), with its main 
function of limiting the spread of ligand, and increasing local concentrations (300). 
Vertebrates
 
have an additional transmembrane protein, Hh-interacting protein
 
(Hip), 
which binds to Hh proteins and reduces their range of
 
movement (301), and is down-
regulated in advanced prostate cancer (302, 303). 
Once it arrives at its destination, hedgehog binds to its receptor molecule Patched, 
a 12 transmembrane receptor with structural homology to the sterol sensing domain of 
HMGCoA reductase, and sterol pumps (304). Binding of Hh is also facilitated by the 
transmembrane protein CDO and Brother of CDO (BOC) (305). Upon ligand binding, 
Patched releases Smoothened from its inhibition, which is of catalytic rather than 
stoichiometric character and is potentially regulated through small molecules (306). 
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Oxysterols (307) and vitamin-D3 derivatives (308) have been proposed as these 
mediators. Smoothened, a 7-pass transmembrane protein, which in its repressed state is 
residing in cytoplasmic vesicles, is now translocating to the primary cilium, which 
requires a functional intraflagellar transport machinery (309). It is in the primary cilium, 
where the activation and processing of Gli transcription factors occurs (310). There are 3 
Gli zinc-finger transcription factors in vertebrates that mediate the hedgehog response. 
Gli1 is reported to exist only in a full length activator form; Gli2, can act as full length 
activator or truncated repressor form (311); and Gli3, which has been reported to only act 
as a repressor by some (312), but not others, which claim, that it directly activates the 
Gli1 promoter (313). Suppressor of Fused (SuFu) is another negative regulator of the 
pathway, sequestering Gli1 in the cytoplasm in the absence of ligand signal (314, 315), 
and mutations of this gene have been found in prostate cancer patients (303, 316). It has 
been found to recruit GSK3beta to process Gli3 (317). Other kinases, specifically PKA 
(318), CK1 (319) and p38 MAPK (320, 321) have been reported as negative regulators of 
the pathway. 
Besides the “classical” hedgehog signaling pathway described briefly here, there 
is emerging evidence of hedgehog pathway components interacting with other pathways, 
like Patched binding directly to Cyclin B1 and caspases to prevent cell proliferation or 
non-Gli mediated pathway responses (322) or its interactions with TGFβ signaling (323). 
 
The hedgehog signaling pathway is crucial in cell fate and patterning, and its role 
in prostate development has been studied by several laboratories (324, 325).  
 
 23 
 
Hedgehog Signaling and Prostate Cancer 
Hedgehog signaling has been found to be important in a number of tumors 
including basal cell carcinomas (326), medulloblastomas (327), gliomas (328), sarcomas 
(329), tumors of the digestive tract (330), small cell lung cancers (331) and pancreatic 
carcinomas (332), and prostate cancer (328, 333-338). In brief, the hedgehog signaling 
pathway proteins Sonic Hedgehog, Patched, Gli and sometimes Smoothened were 
elevated in metastatic prostatic tumors versus normal prostates or non-metastatic tumors. 
Interestingly, hedgehog pathway inhibitors, either cyclopamine or anti-Shh antibodies, 
were able to inhibit in vitro the growth of several well known human prostatic cell lines, 
including LNCaP, PC3, 22RV1 and DU145. More importantly, in vivo in multiple 
xenograft models these same inhibitors worked extraordinarily well to inhibit tumor 
growth and metastases (303, 335, 337, 339). In control experiments, where Gli1 was over 
expressed in various tumor lines, increased in vivo tumor growth was observed and 
because Gli1 is downstream of the inhibitors used, the inhibitors did not inhibit growth of 
these Gli1-over expressing tumors. 
Estrogen and hedgehog signaling is reviewed in chapter IV. 
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General Overview 
 
Chapter II describes the roles of both estrogen receptors, alpha and beta, on 
cancer incidence in the TRAMP mouse. Results from a series of animal studies with 
ERα- and ERβWT and KO mice demonstrated the ERαKO genotype to be protective 
against the aggressive, androgen independent form of prostate cancer, while ERβKO 
mice where twice as likely to develop this metastatic form of cancer. Also, genistein had 
a cancer protective effect, specifically at the more common, slow growing cancer that 
was dose dependent, and required the presence of both estrogen receptors.  
 
 
In chapter III I present data for the presence of autocrine hedgehog signaling in 
epithelial human and mouse prostate cancer cells. I also demonstrate how selected 
botanical compounds inhibit hedgehog signaling at the Gli1 level, which is one of the 
mechanisms they might work through to protect against cancer.  
 
Chapter IV explores the impact of estrogens on the hedgehog signaling pathway. 
Oxysterols, cholesterol derivatives that have been recently proposed to act as SERMs, 
and be responsible for a wide range of unexplained estrogen effects, have now been 
found to stimulate the hedgehog signaling pathway. Both, estrogen and the antiestrogen 
ICI are able to inhibit hedgehog signaling in our assays, and the botanical compounds 
from chapter III are potentially working though one or both estrogen receptors.  
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In chapter V I am proposing future studies that would test some of the hypothesis arising 
from my data and my proposed working model. Specifically, a combinational therapy 
could be developed and tested in the TRAMP model to target both, slow growing, non-
metastatic, and fast growing, androgen-independent prostate cancer subtypes, using 
hedgehog-inhibiting botanicals and ERα antagonists, and ERβ agonists. 
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Figure I-1: Exon structure, primary transcript, and common mRNA splice variants of 
the ER.  
 
(A) The most common splice variants of ERα  are expressed in multiple tissues and arise 
from deletions of internal exons, resulting in truncated proteins lacking segments of the 
DNA-binding domain (DBD) or hormone-binding (ligand-binding) domain (LBD) of the 
receptor. Most variant isoforms possess little transcriptional activity, with the exception of 
ERαΔE5, which binds DNA but lacks most of the LBD, resulting in low levels of 
constitutive activity in some cell lines. ERαΔE3, ERαΔE5, and ERαΔE7 variants have 
demonstrated a dominant-negative effect on transcriptional activity mediated by wild-type 
ER. Adapted from Bollig 2000 (340) and Couse 2006 (341). ERα36 (342) and ERα46 (343) 
as described by Zhao-Yi Wang and Frank Gannon, respectively. 
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(B) Mammalian ERβ variants identified in humans (h), rats (r), mice (m), cows (b), sheep (o), 
and pigs (p). ERβ (ERβ1) possesses both a DBD (C domain) and an LBD (E domain). ERβ2 
codes for a variant that contains an additional 18 amino acids in the LBD, while ERβ1-δ3 
lacks exon 3 and therefore part of the DBD. ERβ2-δ3 contains both of these variations. 
ERβ1-δ5 lacks exon 5, and in ERβCX, the C-terminal 61 amino acids are replaced by a unique 
sequence of 26 amino acids. ERβ4 is truncated at both the N and the C termini. In humans, 
variants lacking exon 2, exon 4, exon 6, and exon 7 also exist. Adapted from Leung 2006 
(344). 
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Figure I-2: Models of estrogen action adapted from Deroo & Korach 2006 (345). 
In the “classical” pathway of estrogen action (i), estrogen or other selective estrogen receptor 
modulators (SERMs) bind to the estrogen receptor (ER), a transcription factor that regulates 
transcription of target genes in the nucleus by binding to estrogen response element (ERE) 
regulatory sequences in target genes and recruiting coregulatory proteins (CoRegs). Rapid or 
“nongenomic” effects of estrogen may also occur through the ER located in or adjacent to the 
plasma membrane (ii), which may require the presence of “adaptor” proteins, which target 
the ER to the membrane. Activation of the membrane ER leads to a rapid change in cellular 
signaling molecules and stimulation of kinase activity, which in turn may affect transcription. 
Lastly, other non-ER membrane-associated estrogen-binding proteins (EBPs) may also 
trigger an intracellular response (iii).  
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Figure I-3: Differential ER structure and coactivator recruitment by ER agonists, 
antagonists, and SERMs.  
Upon binding ER ligands such as estradiol or SERMs, the receptor undergoes a 
conformational change, allowing the ER to exist in a spectrum of conformations from 
active to inactive depending on the nature of the bound ligand. This conformation, in 
turn, regulates the recruitment of specific transcriptional coregulatory proteins and the 
resulting transcriptional apparatus. Coactivators such as SRC1 bind to the active (agonist-
bound) form of the receptor and activate transcription, while corepressors interact with 
the antagonist-bound receptor, inhibiting transcription. Depending on the cellular and 
promoter context, both unique and overlapping sets of genes may be regulated by various 
ligands. Adapted from McDonnell 2002 (346).
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Figure I-4: Model for prostate cancer progression in TRAMP mice. 
 
Adapted from the Norman Greenberg lab webpage: http://thegreenberglab.fhcrc.org 
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Figure I-5: Histological classification of prostate tumor progression in the ERαKO 
TRAMP mouse.  Slides and scoring by Dr. Besch-Williford (87);  descriptions from 
http://thegreenberglab.fhcrc.org/research/TRAMPhistopath 
1. Normal prostate, well defined tubules, single layer of epithelial cells. 
2. Hyperplasia, more numerous epithelial cells with retention of single layer and thin muscle wall 
3. PIN – prostatic intraepithelial neoplasia: epithelial tufting, elongated nuclei, micropapillary 
projections, cribriform structures, nuclear stratification, increased mitosis, increased apoptosis 
4. Well differentiated carcinoma: increased quantity of small glands, desmoplastic response, stromal 
thickening, round nuclei, fewer hyperchromatic nuclei than PIN, increase mitosis, increased 
apoptosis, inflammation frequent 
5. Moderately well differentiated carcinoma: relatively solid growth, glandular architecture +/- 
6. Poorly differentiated carcinoma: anaplastic, sheets of cells, pleiomorphic cells, irregular nuclei, 
glands often trapped, highly vascularized, often hemorrhagic, areas of necrosis, very little 
cytoplasm 
4 
1 2 
5 
3 
6 
Normal Hyperplasia PIN 
WDC MDC PDC 
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Figure I-6: Neuroendocrine-like tumor. 
 
Slides and legend by Dr. Besch-Williford 
 
Sections of mouse prostate probed with antibody to synaptophysin. (A): Basal cells in the 
prostate ducts are positive for synaptophysin, a marker of neuroendocrine cells. The 
prostate secretory epithelium is synaptophysin negative. (B): A focus of neuroendocrine 
cell proliferation, the earliest stage of neuroendocrine-like neoplasia. (C): The neoplastic 
neuroendocrine cells penetrate through the wall of the prostate tubule and proliferate in 
the stroma, encroaching adjacent tubules and eventually surrounding the urethra (D). 
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Figure I -5: The Hedgehog pathway in vertrebrates.  
 
In the absence of ligand, Patched will inhibit Smoothened, through an unknown 
mechanism, possibly enzymatically or by use of small inhibitory molecules (A). Upon 
hedgehog binding, the inhibition of Smoothened is released, and it is now free to 
translocate to the primary cilium and activate Gli transcription factors (B). Cyclopamine 
can directly bind to Smoothened and prevent it from entering the cilium. Interestingly, 
even thought there is a significant conservation of pathway members, specifically 
Smoothened, cyclopamine will not inhibit the pathway in Drosophila (347). 
 
A  B 
 
cyclopamine 
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Figure I-6: Conserved hedgehog pathway - adapted from Varjosalo & Taipale 2007 
(348).
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II - Genistein Reduces Incidence of Prostate Cancer in TRAMP mice 
through Estrogen Receptor Dependent Mechanism 
 
Overview 
 
The purpose of this animal study was to test the cancer preventative role of 
genistein in the TRAMP prostate cancer model and to elicit its mechanism through the 
use of Estrogen Receptor-alpha and -beta KO mice. We expected genistein to prevent and 
delay cancer incidence in WT animals in a dose dependent manner, which is what we 
observed. Our hypothesis was that genistein worked primarily through ERβ. We also 
expected to see a absent or reduced protective effect of genistein in the ERβKO animals, 
but not, or to a lesser degree in the ERαKO mice. 
We were surprised to see that genistein only affected the WDC incidence, but had 
no effect on PDC. Another unexpected result was the fact that genistein had no effect in 
either the ERα- or ERβKOs. We were really intrigued by the very strong genotypic 
effects on cancer incidence, a protective effect in ERαKO mice, which got only 5% PDC, 
and an increase in the incidence of aggressive PDC in ERβKO mice.  
 
 36 
Introduction 
Dietary consumption of soy products has long been associated with reduced 
incidence of various diseases. Considerable epidemiological evidence supports the 
observation that soy foods promote health and reduce chronic ailments including 
cardiovascular disease and osteoporosis (349, 350). Genistein has been implicated as 
cancer preventative through epidemiological studies (351, 352) as well as targeted in 
vitro (353) and in vivo (354-356) studies. The cancer incidence for breast (357) and 
prostate (358) cancer is significantly lower in cultures with high soy consumption (359) 
and high serum genistein levels.  
 
Estrogen therapy, specifically DES treatment, has been used in prostate cancer 
treatment since 1941 (43, 360-363). The importance of estrogens and estrogen receptors 
in the prostate has been recognized both in the organ development (364) and disease 
(365). 
ERα is expressed in the stromal compartment of the normal adult mouse prostate, 
while ERβ can be found in the prostatic epithelial cells (366). In the rat prostate ERβ is 
expressed in both cell types at birth, but steadily declines in the mesenchyme, and reaches 
maximal adult levels in the epithelium by day 90, upon completion of differentiation 
(367). Neonatal estrogen exposure has profound effects on prostate development both in 
the rodent (29, 368-371) and human (372). 
 
Genistein has a multitude of documented mechanisms of action, here we wanted 
to investigate to what degree its cancer protective effects could be attributed to its 
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estrogenic activity. By using both ERα- and ERβKO mice in conjunction with mice with 
both receptors intact we were able to demonstrate that actually both receptors are 
required for genistein to have an effect in preventing prostate carcinogenesis. 
 
Materials and Methods 
TRAMP mouse studies 
The TRAMP model was developed by placing the SV40 large and small T-antigen gene 
under the control of the androgen regulated rat probasin promoter, which has been shown 
to be highly and specifically expressed in the mouse prostate (39, 373). TRAMP mice 
spontaneously develop prostate tumors starting at the age of three months and they can be 
used to study the progression of the disease, as well as prevention and treatment options.  
Male TRAMP mice on a C57BL6/J background were raised in-house. All University of 
Missouri institutional guidelines for animal care and use were followed. 
To generate the ERα/βKO-TRAMP mice, female C57Bl/6J mice, heterozygous for the 
ERα or ERβ gene and positive for the PBTag Transgene (TRAMP) were crossed with 
male C57Bl/6J mice that were heterozygous for the ERα/β gene and negative for the 
PBTag transgene.   All breeder pairs were maintained on a casein-based diet (AIN 93G) 
with casein from MP Biomedical LLC (Aurora, Ohio).  ERWT, ERαKO and ERβKO 
offspring of this breeding scheme, that were positive for the PBTag transgene, were used 
in this study. 
The mice were housed in pairs in micro-isolator cages and given free access to food and 
water. A daily light:dark cycle of 12:12h  was used, with ambient temperature and 
humidity set at 21°C, and 50%, respectively. Animals were monitored weekly for body 
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weight and tumor burden. The mice were fed the casein-based diet (AIN93G) until 
weaning, and then randomly assigned to groups fed either the control casein diet or the 
experimental genistein diet which consisted of the same base diet AIN93G (374) to 
which  300mg/kg or 750 mg/kg genistein (LC Laboratories, Woburn, MA) has been 
added. The mice were maintained in the study from 5-6 weeks until 5 months (18-22 
mice per treatment group). The concentration of genistein was selected after analyzing 
serum concentrations of mice consuming a range of diets from 0 gm genistein / kg diet to 
500 mg genistein / kg diet in 100 mg increments (data not shown).  The goal was to 
provide a concentration of dietary genistein which resulted in serum concentrations 
below 1-5μM range. Tyrosine kinase inhibition will not occur (375), but these 
concentrations will saturate both estrogen receptors. 
At 5 months mice were euthanized and tissues were collected. The reproductive tract 
(testes, vas deferens, empty urinary bladder, seminal vesicles and prostate lobes), testes, 
and prostates were weighed. At the time of collection, a portion of each prostate was 
fixed in neutral buffered formalin and paraffin embedded for histological analysis and the 
remainder snap-frozen in liquid nitrogen and stored at -80
O
C. Tissues sections were 
stained with hematoxylin and eosin, and examined by light microscopy for assessment of 
cancer stages (376). Prostates were scanned by trained veterinary pathologists who were 
unaware of the treatment groups and staged as either (A) normal, (B) hyperplastic, (C) 
prostatic intraepithelial neoplasia (PIN), (D) well-differentiated carcinoma (WDC), (E) 
moderately well-differentiated carcinoma (MDC), (F) poorly differentiated carcinoma 
(PDC) “ neuro-endocrine- like carcinoma” (Figure I-2). This protocol follows a 
procedure described previously (87, 89). 
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Immunohistochemistry: 
Slides were prepared using heat mediated antigen retrieval. Immunohistochemistry 
reactions were performed using the DakoCytomation Autostainer (Dako, Carpinteria 
(CA). Primary antibodies were used in the following dilutions: SV40 Tag Pab101 1:200 
(Pharmingen), Chromogranin A&B 1:50 (RDI), Synaptophysin 1:100 (Dako), AR RG-21 
1:50 (Upstate), ERα MC-20 1:300 (Santa Cruz, CA), ERβ PPG5/10 1:50 (Serotec). 
Scoring was done by Dr. Besch-Williford.  
 
Cell Culture: 
The TRAMP-C2 cell lines was obtained from ATCC (http://www.atcc.org). PC3M cells 
(377), which is a highly metastatic form of PC3 was obtained from our in house cell core 
(www.biotech.missouri.edu/cic). 
Mouse prostate cancer TRAMP-C2 and human prostate cancer PC3M cell lines were 
maintained in RPMI 1640 media supplemented to contain 10% fetal bovine serum (U.S. 
Bio-Technologies, Parkerford, PA), 4.5g/mL Glucose, 4mM L-glutamine , 100 M Non-
essential Amino Acids, 10mM HEPES, 1mM Sodium Pyruvate, and 1% Penicillin/ 
Streptomycin (all from Invitrogen, Carlsbad, CA). 
 
Protein Assay: 
All compound treatments for the growth assessment consisted of a 72-hour time course in 
phenol red-free RPMI 1640 medium, supplemented with 10% charcoal-stripped FBS. 
Cells were seeded in 12-well plates and adjusted to phenol-red free medium for 24 hours. 
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TRAMP-C2 cells were treated at 30-40% confluency, PC3M cells at 40%, which allowed 
the controls to reach 100% by day 3. Cells were lysed with 1N NaOH and left overnight. 
Protein assays to measure overall cell protein concentration were performed using Bio-
Rad Dc kit (Bio-Rad, Hercules, CA), with absorbance measured at 699nm. Compounds 
were used at concentrations ranging from 1μM to 100μM in half log increments. Each 
experiment was performed at least three times in duplicate. Total cellular protein 
correlates well with thymidine uptake in prostate cancer cells and is a reliable assay to 
measure cell growth (111). 
 
Statistical Analysis    
The stages of tumor incidence were classified into non-cancer stages (Normal, 
Hyperplasia and PIN) and cancer stages (WDC, MDC, and PDC or neuro-endocrine like 
carcinoma). Tumor incidence data was analyzed as a 2 x 2 factorial with genotype 
(ERαWT or ERαKO) and diet (casein or genistein) as main effects using χ2 test, after 
consultation with Dr. Lamberson. Values that achieved p<0.05 were considered to be 
significantly different. Comparison within the same tumor stage among different dietary 
groups and genotypes has also been done. Body weight, reproductive tract weight, 
testicular weight, and prostate weight were analyzed using a two-sample t-test, assuming 
unequal variance. GraphPad Prism4 software was used to perform the analysis 
(www.graphpad.com, La Jolla, CA). 
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Results 
Genistein’s effect on cancer incidence in TRAMP 
Genistein significantly reduced overall cancer incidence in ERWT animals 
compared to control diet in a dose dependent manner (Table II-1). Specifically WDC 
incidence was extremely decreased from 49% in the control to 18% with low dose 
(300mg/kg) and 8% with high dose (750mg/kg) genistein. No effect on PDC incidence 
were observed, contrary to what was reported before (356). Genistein had no effect in 
ERαKO or ERβKO animals (Table II-2). 
 
Estrogen Receptor status and cancer incidence 
Approximately 70% of TRAMP mice wild type for both estrogen receptors 
developed cancer by 5 months of age, with WDC incidence of ~50% and PDC incidence 
of ~20%. Mice lacking ERα had an increased WDC incidence at ~85% however they 
have a greatly reduced PDC incidence with only 5%. ERβKO TRAMP mice however 
have over 40% PDC, indicating a possible protective role for ERβ in tumorigenesis, or a 
tumorigenic role of ERα, or a combination of both (Table II-2). 
 
Immunohistochemistry - Estrogen Receptor profile changes with cancer progression 
In order to have a better understanding of the involvement of estrogen receptors in 
cancer progression we have performed immunohistochemical analyses of hormonal 
receptor expression in the prostates from TRAMP mice. We have also looked at the 
expression of the neurondocrine markers chromogranin A and synaptophysin, which have 
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been proposed to be expressed by the aggressive neuroendocrine-like tumors, and hat are 
being investigated as biomarkers for metastatic prostate cancer in patients (378-381).  
Shown in Figure II-4 are representative tissue samples from two ERWT/TRAMP 
mice (4448 and 4264) fed genistein with HYP (top) from the dorsal lobe or PDC 
(bottom) from the ventral lobe.  Hyperplastic prostate epithelium does not express 
chromogranin and synaptophysin, both cytoplasmic neuroendocrine (NE) markers, nor 
ERβ. There is expression of ERβ and androgen receptor in epithelial and stromal cells, as 
has been reported for normal prostate epithelium in man and mouse. The SV40 
immunoreactivity confirms the expression of the transgene in the nucleus of the prostate 
epithelium. The immunoreactivity to this panel of antibodies of the HYP prostate was not 
different from those fed casein. As shown in Figure II-4, bottom, these markers differed 
in PDC tissues. There was no difference between casein and genistein fed mice. In 
contrast to the hyperplastic prostate, neuro-endocrine carcinoma in this TRAMP model 
did express neuroendocrine markers, with 80% of sections expressing synaptophysin, and 
30% expressing chromogranin. Androgen receptor reactivity diminished from occasional 
weak positives to uniformly negative. Transgene expression was maintained in NE cells. 
Interestingly, the pattern of estrogen receptor immunoreactivity switched, with nearly 
 expression and gain of ERα expression. The pattern of ERα 
immunoreactivity was predominantly in clusters of NE cells scattered throughout the 
tumor mass and not in all NE cells. In data not shown, ERα expression was also observed 
in PIN and well-differentiated adenocarcinoma cells in both diet groups. Hence, distinct 
cancer origins appear to occur in the TRAMP prostate and these are independent of diet. 
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We will further our exploration of these events in order to more fully relate this animal 
model to human prostate cancer. 
 
Weights differences 
High dose genistein in the wildtype and in ERαKO mice significantly increased 
total bodyweights (Figure II-1), with 28.8±0.22g and 29.74±0.52g in the casein fed WT 
and αKO vs. 30.18±0.68g and 32.38±0.81g in the high dose genistein fed WT and αKO 
mice (Table II-4). It has been reported that genistein contributes to increased lean body 
mass in neutered cats (382), and food intake and total body mass in quails (383). 
ERαKO mice had significant lower testes weights which is corresponding to 
previous reports (384) and the observed lower fertility in both ERαKO mice (385) and 
one human male (386, 387). There is still some controversy regarding the main ER in the 
testis - Gustafsson claims ERβ is main receptor in testis (388),  Kathenellenbogen votes 
for ERα (389). We did not observe any differences in testis between ERWT and ERβKO 
mice. 
 Total prostate weights did not vary between groups due to significant variance in 
tumor size, specifically within the PDC tumors (Figure II-3A). When separated into two 
groups with a cut-off weight of 1.5g however, there were visible pattern with significant 
differences between groups. The separation by weight was used to determine whether 
there were differences between groups within the same cancer stage. It is a gross way to 
characterize the proliferation of the tumors, and will be followed up by Ki67 staining. 
Prostates over 1.5g, which were exclusively PDCs, were most highly represented 
in the ERWT casein group - 7/175, and 6/81 in the ERWT low genistein group. The 
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weights of those large tumors were highest in the ERWT low genistein group, followed 
by ERWT casein, and ERWT high genistein being same as ERβKO genistein. This is 
interesting to note that even though ERβKO mice had a significantly higher PDC 
incidence relative to control their tumor weights were not higher. ERαKO mice had only 
1 tumor above 1.5g corresponding to the overall absence of PDC in ERαKOs (n=105) 
(Figure II-3B). Within the prostates under 1.5g, ERαKO mice had significant higher 
weight compared to the other genotypes (Figure II-3C), corresponding to the increased 
WDC incidence in ERαKO mice (Table II-2).  
 
Genistein inhibits prostate cancer cell growth in vitro 
We and others have previously reported on the inhibitory growth effect of 
genistein on prostate cancer cells – LNCaP and PC3 (111, 218). Here we showed how 
genistein is able to inhibit cell growth in mouse TRAMP-C2 cells starting at 100nM and 
human PC3M cells starting at 10nM (Figure II-5). 
 
Estradiol or ICI alone will not inhibit prostate cancer cell growth, together however 
they will. 
Neither 17β-estadiol, nor the pure anti-estrogen ICI alone are able to inhibit 
prostate cancer cell growth in TRAMP-C2 or PC3M cells. When administered together 
however, they will decrease total cellular protein in both cell lines in a dose dependent 
manner, starting with 1nM E2 + 100nM ICI (Figure II-5), for discussion see chapter IV. 
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Discussion 
We were able to confirm our hypothesis of genistein being protective against 
prostate tumorigenesis (Figure II-2), however our data showed that it is not solely acting 
through ERβ. The fact that genistein had no effect on total cancer incidence in either 
ERKO animal group indicates that genistein requires both estrogen receptors present in 
order to enact its protective action.  
 
A surprising observation that came out of the first animal study with ERWT and 
ERαKO mice, was further confirmed with follow-up studies (Table II-3), was that of the 
opposing roles the two estrogen receptors were playing in carcinogenesis. ERαKO 
animals had almost no PDC indicence (4%), and ERβKO mice had double the PDCs 
(42%) compared with WT mice (22%) (Table II-1).  
 
It is also possible that the genotypic effect that we observed is dominant over any 
dietary treatment. In our many parallel dietary studies with mixes of flavones and 
isoflavones in TRAMP mice, we were not able to see any dietary effect in ERαKO 
animals compared to animals WT for both receptors (data not shown). 
Comparing the prostate weights by stage between the groups, we observed an 
interesting phenomenon. Besides of having an increased WDC incidence, which is 
responsible the overall increase in cancer, the ERαKO mice had significantly higher 
tumor weights compared to both ERWT and ERβKO mice. It is interesting still that even 
though it seems as they had a more aggressively growing cancer, it did not progress to the 
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poorly differentiated carcinoma stage. Studies with aged ERαKO mice showed that they 
did not develop more PDC up to 8 months (data not shown). 
ERβKO mice were also bearing a surprise in it they had smaller tumors, and less tumors 
over 1.5g than control even though they had double the PDC incidence. It would be 
interesting to see whether those PDC tumors differed in other aspects, like expression of 
neuroendocrine markers or proliferation markers.  
 
 The immunohistochemical analysis is in agreement with our new hypothesis 
about the importance of ERα and ERβ in cancer progression. The non-cancerous, 
hyperplastic prostate did express ERβ, but not ERα. It also expressed AR, corresponding 
with the initial responsiveness to androgens in the prostate. In the PDC however, the 
expression pattern switches to ERα-positive cells that lack ERβ. The androgen is also lost 
at this stage as is the androgen responsiveness. The picture of the protective ERβ and 
tumorigenic ERα is very suggestive. 
 
Another player in the prostate is the DHT metabolite, 5-androstene-3β, 17β-diol, 
which is able to bind to both estrogen receptors in vitro (215), with affinities of 6nM and 
2nM, respectively, however it was reported to preferentially activate ERβ. It is possible, 
that the protective effect against PDC in the ERαKO mice is mediated through 5-
androstene-3β, 17β-diol via ERβ. Removal of the “good” receptor in the ERβKO mouse 
leads thus to a doubling in PDC incidence (Figure II-6).  
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 We also observed an antiproliferative effect of genistein in vitro, both in human 
and mouse prostate cancer cells (Figure II-5). We do not see the initial stimulatory effect 
of low dose genistein, as observed in PC3 and LNCaP by us ((111) and data not shown), 
and others.  
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Genotype Diet n 
Tumor Stage 
Non-Cancer Cancer 
Normal HYP PIN WDC MDC PDC 
ERWT Casein 175 2 (1%) 10 (6%) 41 (23%) 88 (50%) 0 34 (19%) 
ERWT Genistein 
300mg/kg 
81 1 (1%) 13 (16%) 29 (36%) 15 (19%) 1 (1%) 22 (27%) 
ERWT Genistein 
750mg/kg 
25 0 0 17 (68%) 2 (8%) 0 6 (24%) 
         
ERαKO Casein 80 0 3 (4%) 4 (5%) 68 (85%) 1 (1%) 4 (5%) 
ERαKO Genistein 25 0 0 1 (4%) 23 (92%) 1 (4%) 0 
         
ERβKO Casein 51 0 0 13 (25%) 18 (35%) 0 20 (39%) 
ERβKO Genistein 23 0 0 5 (22%) 8 (35%) 0 10 (43%) 
 
Table II-1: Effect of diet and genotype on the incidence of prostate cancer in 5 
month old TRAMP mice. 
 
Fisher’s exact test two-tailed P-value 
PDC incidence:  ERWT vs ERαKO 0.0021 
   ERWT vs ERβKO 0.0027 
Very statistically significant genotype effect. 
No significant dietary effect.  
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WDC incidence: within ERWT low and high dose genistein vs casein 0.0001, 
extremely significant 
 
Within casein   ERWT vs ERαKO >0.0001, extremely significant 
   ERWT vs ERβKO 0.0572, not quite significant 
 
Within ERWT  casein vs low genistein >0.0001, extremely significant 
   Casein vs high gensitein >0.0001, extremely significant 
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Genotype Diet n 
Tumor Stage 
Non-Cancer Cancer 
ERWT Casein 175 53 (30%) 122 (70%) 
ERWT Genistein 
300mg/kg 
81 43 (53%)*** 38 (47%)*** 
ERWT Genistein 
750mg/kg 
25 17 (68%)*** 8 (32%)*** 
 
ERαKO Casein 80 7 (9%)*** 73 (91%)*** 
ERαKO Genistein 
300mg/kg 
25 1 (4%)** 24 (96%)** 
 
ERβKO Casein 51 13 (25%) 38 (75%) 
ERβKO Genistein 
300mg/kg 
23 5 (22%) 18 (78%) 
 
 
Table II-2: Effect of diet and genotype on the incidence of prostate cancer in 5 
month old TRAMP mice. 
 
Non-cancer was defined as normal, hyperplasia, and prostatic intraepithelial neoplasia. 
Cancer was defined as well-, moderately-, and poorly differentiated carcinoma.  
Each group was compared with ERWT casein. 
** p<0.005 – very statistically significant; *** p<0.001 extremely statistically significant. 
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1. ERαKO genistein 2x2 study 1033-01 
Genotype Diet n 
Tumor Stage 
Non-Cancer Cancer 
Normal HYP PIN WDC MDC PDC 
ERαWT Casein 25  2 (8%) 4 (16%) 1 (4%) 13 (52%) 0 5 (20%) 
ERαWT Genistein 
300mg/kg 
28 1 (4%) 10 (36%) 7 (25%) 6 (21%) 0 4 (14%) 
         
ERαKO Casein 29 0 1 (3%) 0 25 (86%) 1 (3%) 2 (7%) 
ERαKO Genistein 
300mg/kg 
25
 
 0 0  1 (4%) 23 (92%) 1 (4%) 0 
mice collected  5/7/2001-12/6 2001 
deaths: WT cas 4888 died at 5 months 
            αKO cas 4880 died at 5 months 
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2. Pygeum study 1001-04 
Genotype Diet n 
Tumor Stage 
Non-Cancer Cancer 
Normal HYP PIN WDC MDC PDC 
ERαWT Casein 16 0 0 6 (37.5%) 8 (50%) 0 2 (12.5%) 
mice collected 12/9/2003 – 5/1/2004 
deaths: WT cas 9805 died at 4½ months 
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3. Isoflavone 7 Mix study 1023-03 
Genotype Diet n 
Tumor Stage 
Non-Cancer Cancer 
Normal HYP PIN WDC MDC PDC 
ERαWT Casein 22  0 1 (4%) 2 (9%) 14 (64%) 0 5 (23%) 
ERαKO Casein 20 0 1 (5%) 4 (20%) 15 (75%) 0 0 
mice collected 4/13/2003-12/2/2003 
deaths: αKO casein 9178 died at 4½ months 
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4. Daidzein PCSpez study 1009-02 
Genotype Diet n 
Tumor Stage 
Non-Cancer Cancer 
Normal HYP PIN WDC MDC PDC 
ERαWT Casein 27  0 5 (18.5%) 8 (30%) 9 (33%) 0 5 (18.5%) 
ERαKO Casein 31 0 1 (3%) 0 28 (90%) 0 2 (6%) 
mice collected 1/9/2002-3/3/2003 
deaths: WT cas 880 died at 4¾ months 
 WT cas 9004 died at 5 months 
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5. ERβKO genistein 2x2 study 1042-04 
Genotype Diet n 
Tumor Stage 
Non-Cancer Cancer 
Normal HYP PIN WDC MDC PDC 
ERWT Casein 29
 
 0 0 8 (28%) 14 (48%) 0 7 (24%) 
ERWT Genistein 
300mg/kg 
25 0 3 (12%) 10 (40%) 1 (4%) 1 (4%) 10 (40%) 
         
ERβKO Casein 25 0 0 4 (16%) 8 (32%) 0 13 (52%) 
ERβKO Genistein 
300mg/kg 
23 0 0  5 (22%) 8 (35%) 0 10 (43%) 
mice collected 3/27/2004-7/8/2005 
deaths: βKO cas 1539 large tumor, culled at 4½ months 
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6. Hi-lo genistein 1084-07 
Genotype Diet n 
Tumor Stage 
Non-Cancer Cancer 
Normal HYP PIN WDC MDC PDC 
ERWT Casein 28 0 0 7 (25%) 16 (57%) 0 5 (18%) 
ERWT Genistein 
300mg/kg 
28 0 0 12 (43%) 8 (29%) 0 8 (29%) 
ERWT Genistein 
750mg/kg 
25 0 0 17 (68%) 2 (8%) 0 6 (24%) 
mice collected 6/21/2007-9/8/2007 
deaths: WT hi gen 5153 culled at 4½ months due to poor health 
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7. New berko 1049-09 
Genotype Diet n 
Tumor Stage 
Non-Cancer Cancer 
Normal HYP PIN WDC MDC PDC 
ERWT Casein 28 0 0 9 (32%) 14 (50%) 0 5 (18%) 
ERβKO Casein 26 0 0 9 (35%) 10 (38%) 0 7 (27%) 
mice collected 11/16/2007-2/27/2008 
deaths: βKO casein 9928 died at 4¾ months 
 
Table II-3: Tumor incidence for TRAMP mice split by separate study.  
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Weights (gm) 
Genotype 
Diet Body Repro. Tract Prostate Testes 
ERWT 
Casein 28.80 ± 0.22
a
 1.41 ± 0.10
a
 0.40 ± 0.10
a
 0.21 ± 0.004
a
 
ERWT 
Genistein
low
 28.92 ± 0.33
a
 1.78 ± 0.26
ad
 0.81 ± 0.27
a
 0.20 ± 0.004
a
 
ERWT 
Genistein
high
 30.18 ± 0.68
b
 1.35 ± 0.18
a
 0.28 ± 0.17
a
 0.21 ± 0.005
a
 
 
     
ERαKO 
Casein 29.74 ± 0.52
a
 3.02 ± 0.18
b
 0.33 ± 0.03
a
 0.17 ± 0.011
b
 
ERαKO 
Genistein 32.38 ± 0.81
c
 3.98 ± 0.24
c
 0.43 ± 0.03
a
 0.18 ± 0.018
ab
 
 
     
ERβKO 
Casein 28.16 ± 0.52
a
 2.20 ± 0.32
d
 0.54 ± 0.19
a
 0.20 ± 0.003
a
 
ERβKO 
Genistein 28.49 ± 0.42
a
 1.76 ± 0.36
ad
 0.83 ± 0.39
a
 0.21 ± 0.006
a
 
 
Table II-4: Body and organ weights of mice from different dietary groups. 
 
Means ± SEM.  Values within columns with different letter superscripts are significantly 
different, p<0.05. 
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Figure II-1: Mouse body weight from all studies combined.  
 
For statistics between groups see Table II-4. 
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Figure II-2: TRAMP mouse urogenital tract (A) and testes (B) weights. 
 
ERαKO mice have significant lower testes weights.
A B 
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Figure II-3: Weights for 5 month old TRAMP mouse prostates  
When combined as in (A), there are no significant differences in prostate weights, when 
we applied a cut-off of 1.5g for very large prostate, which were predominantly PDCs, we 
obtained a more differentiated pattern for prostate weight above 1.5g (B), and under 1.5g 
(C). ERWT mice on casein and low dose genistein.
A B 
C 
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Top: Prostatic Hyperplasia  
Bottom: Poorly Differentiated Carcinoma (PDC) 
 
Figure II-4: Immunohistochemistry for T-antigen, neuron-endocrine markers, and 
sex-steroid receptors in TRAMP prostates.  
 
In both panels, the brown regions represent immunoreactivity. The immunoreactivity to 
this panel of antibodies of the prostate was not different from those fed casein.
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Figure II-5: Effects of Genistein, E2 and ICI on prostate cancer cell growth.  
 
TRAMP-C2 (A) and PC3M (B) cells were treated for 72 hours with genistein, E2, ICI, or 
E2+100nM ICI. Cells were lysed with 1N NaOH for 24 hours, following an assay for 
total cellular protein.  
A 
B 
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Figure II-6: 5α-androstane-3β,17β-diol in the prostate. 
 
5α-androstane-3β,17β-diol can be converted from its androgen precursor, 5α-dihydro-
testosterone (DHT), by a variety of steroid metabolizing
 
enzymes, including: 17ß-
hydroxysteroid dehydrogenase (17ßHSD), 3α-hydroxysteroid oxidoreductase (3αHSD), 
and 3ß hydroxysteroid oxidoreductase (3ßHSD) (390).  
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III - Common Botanical Compounds Inhibit the Hedgehog Signaling 
Pathway in Prostate Cancer. 
 
Overview 
 
Many botanical compounds have been proposed to prevent cancer. We 
investigated the cancer treatment and prevention abilities of apigenin, baicalein, 
curcumin, EGCG, genistein, quercetin, and resveratrol, both in vivo in TRAMP 
(TRansgenic Adenocarcinoma of the Mouse Prostate) mice, as well as in vitro in prostate 
cancer cell lines.  
In our experiments we hypothesized that these seven compounds act similarly to 
the hedgehog antagonist, cyclopamine, a teratogenic plant alkaloid, which had been 
previously shown to “cure” prostate cancer in a mouse xenograft model by inhibiting the 
hedgehog signaling pathway. With IC50 values ranging from <1μM to 25μM these 
compounds demonstrated hedgehog pathway inhibition by deceasing Gli1 mRNA 
concentration by up to 95% and down regulating Gli-reporter activity by 80%.  
We show that four compounds, genistein, curcumin, EGCG, and resveratrol, 
inhibit hedgehog signaling as monitored by real-time RT-PCR analysis of Gli1 mRNA 
concentration or by Gli-reporter activity. Three compounds, apigenin, baicalein, and 
quercetin, decreased Gli1 mRNA concentration but not Gli-reporter activity. 
Our results show that these compounds are also able to reduce or delay prostate 
cancer in vivo in TRAMP mice. All 7 compounds, when fed in combination as pure 
compounds or as crude plant extracts, inhibit well differentiated carcinoma of the prostate 
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by 58% and 81%, respectively. In vitro we show that all 7 compounds also inhibit cell 
growth in human as well as mouse prostate cancer cell lines. In vitro experiments show 
also that low concentrations of each botanical, which are not quite inhibitory to Gli1 
when used alone, act synergistically, when used in combinations corresponding to mixes 
used in the mouse diets in our in vivo studies.  
Mechanistically, we propose the hedgehog-signaling pathway to be a direct or 
indirect target of these compounds. These botanicals at pharmacological concentrations 
are potentially safer and less expensive alternatives to cyclopamine and its 
pharmaceutical analogs for cancer therapy.
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Introduction: 
Prostate cancer remains the second most commonly diagnosed cancer in the USA.  
According to the Prostate Cancer Foundation, for every three men diagnosed with cancer, 
one will be diagnosed with prostate cancer. It is also the second leading cause of cancer 
deaths of men in the United States (1). Because prostate cancer typically develops later in 
life, identifying botanical compounds that delay the progression of this disease will have 
a positive impact on quality of life, and reduce healthcare costs of the aging population.  
 
It is well known that diet and other environmental factors can greatly reduce the 
risk of cancer incidence. In particular, dietary phytoestrogens and antioxidants have been 
implicated in protecting against cancer (111, 391). We have selected a group of 7 
botanical compounds that have been reported by our lab and others to have prostate 
cancer protective activities (111, 128). They have been widely used in traditional 
medicine and in dietary supplements that are currently available in the United States 
(392). Those compounds include apigenin from Matricaria recutita (chamomile), 
baicalein from Scutellaria baicalensis Georgi (Chinese skullcap), curcumin from 
Curcuma longa (turmeric), EGCG (Epigallocatechin 3-gallate) from Camellia sinensis 
Kuntze (green tea), genistein from Glycine max (soy), quercetin from Ginkgo biloba and 
resveratrol from Vitis vinifera (grape).   
 
We have previously reported on the cancer preventive effect of each of these 7 
compounds in PC3 and LNCaP human prostate cancer cell lines (111). Here we show 
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that all 7 can individually also inhibit growth of the mouse prostate cancer cell line 
TRAMP-C2 (88). 
Pursuant to these results, we wanted to determine whether these seven botanical 
compounds would impact the hedgehog signaling pathway, which, through its inhibitor 
cyclopamine, has been recently found to be important in prostate cancer and its treatment 
(303, 335, 337, 339).  
 
The hedgehog (Hh) signal-transduction pathway is crucial to the growth, survival 
and organization of many cells, tissues and organs. Dysregulation of the Hh signal-
transduction pathway has been implicated in several cancers, including human prostate 
cancer (335, 337, 339, 393). The pathway is activated by one of three types of Hedgehog 
protein, Sonic, Desert or Indian. These are secreted glycoproteins that bind to their 
membrane receptors, Patched1 or Patched2, which in turn relieve the inhibition of 
another trans-membrane protein, Smoothened. Smoothened mediates its actions via three 
transcription factors in the Gli family, specifically Gli1, Gli2 and Gli3 proteins (Figures 
I-5 & I-6). Several types of cancer, including medulloblastomas, lung, esophageal, skin, 
pancreas, and prostate cancer, show greatly increased hedgehog pathway activation. 
Therefore, inhibition of Gli function might be a promising prevention and therapeutic 
target in certain tumors.  
 
We found that four of the seven botanical compounds can inhibit the hedgehog-
signaling pathway in vitro, both in the prostate cancer TRAMP-C2 cells, as well as in an 
established hedgehog pathway assay in Shh Light II cells.  
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We propose that the prostate cancer preventative effects of these dietary 
botanicals may result from inhibition of the hedgehog pathway, and that they potentially 
represent an inexpensive, safe and effective alternative to cyclopamine in cancer 
prevention and treatment.  
 
Materials and Methods: 
Diet formulations and sources: 
Curcumin, baicalein and soy isoflavones were provided by Dr. Acharan Narula (Narula 
Research, Chapel Hill, NC). EGCG, resveratrol, and quercetin were purchased from 
Sigma Chemical Co. (St. Louis, MO). Apigenin and genistein were purchased from LC 
Laboratories (Woburn, MA). Sencha leaves, curcuma longa roots, yucca roots, saw 
palmetto, chamomile flowers, and gingko were purchased from Frontier Natural Products 
Co-op. (Norway, IA). Experimental diets were based on the AIN93G formulation (374). 
All diets contained the same formulation, with addition of botanical ingredients 
substituted by weight for cornstarch. The controlled diet contained no added botanicals 
(Casein). The Pure 3 Diet contained 10g/kg curcumin, 100mg/kg EGCG and 10mg/kg 
resveratrol; the Pure 4 Diet contained 15mg/kg apigenin, 150mg/kg baicalein, 250mg/kg 
genistein, and 1g/kg quercetin; the Pure 7 Diet included all 7 pure compounds at the same 
level as in the 3 and 4 mix diets; and the Crude 7 Diet contained 1% w/w of the following 
dried herbs: sencha leaves, curcuma longa roots, yucca roots, saw palmetto (in lieu of 
Scutalaria baicalensis), chamomile flowers, gingko and soy isoflavone extract. The herbs 
were ground in a coffee mill prior to mixing into the diets and care was taken to ensure 
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complete uniform mixing of all ingredients. The concentrations of pure compounds 
represent a high-end dietary intake in humans, and were scaled proportionally for mice.  
 
TRAMP mouse studies: 
The TRAMP model was developed by inactivating two tumor suppressing genes, Rb and 
p53, by placing the SV40 large and small T-antigen gene under the control of the 
androgen regulated rat probasin promoter, which has been shown to be highly and 
specifically expressed in the mouse prostate (39, 373). TRAMP mice spontaneously 
develop prostate tumors starting at the age of three months and they can be used to study 
the progression of the disease, as well as prevention and treatment options.  
Male TRAMP mice on a C57BL6/J background were raised in-house. All University of 
Missouri institutional guidelines for animal care and use were followed. The mice were 
housed in pairs in micro-isolator cages and given free access to food and water. A daily 
light:dark cycle of 12:12h  was used, with ambient temperature and humidity set at 21°C, 
and 50%, respectively. Animals were monitored weekly for body weight and tumor 
burden. The mice were fed the specific diets from 5 weeks until 5 months (18-22 mice 
per treatment group). Prostates were collected, formalin fixed and paraffin embedded. 
Tissues sections were stained with hematoxylin and eosin, and examined by light 
microscopy for assessment of cancer stages (376). 
All TRAMP mice were wild type for estrogen receptors except for the Crude 7 study, in 
which both casein control and experimental mice were heterozygous for ER  (394). The 
cancer incidence did not vary between WT and ER heterozygous mice. 
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Cell Culture: 
All cell lines were obtained from ATCC (http://www.atcc.org). 
Mouse prostate cancer TRAMP-C2 and human prostate cancer PC3 cell lines were 
maintained in RPMI 1640 media supplemented to contain 10% fetal bovine serum (U.S. 
Bio-Technologies, Parkerford, PA), 4.5g/mL Glucose, 4mM L-glutamine , 100 M Non-
essential Amino Acids, 10mM HEPES, 1mM Sodium Pyruvate, and 1% Penicillin/ 
Streptomycin (all from Invitrogen, Carlsbad, CA). 
Shh Light II cells (JHU-68) were maintained in Dulbecco's modified Eagle's medium 
with 4mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate and 4.5 g/L 
glucose supplemented with 0.4 mg/ml G-418, 0.15 mg/ml Zeocin (Invitrogen), and 10% 
fetal bovine serum. This mouse embryonal NIH 3T3 cell line contains a stably transfected 
luciferase  reporter with 8 copies of the consensus Gli binding site derived from the 
mouse Hepatocyte Nuclear Factor-3β (JHU-73 pGL3B/8XgliBS-lc-luc 5’-
GAACACCCA-3’) (395). 
The purified compounds used in tissue culture experiments were obtained from the 
following suppliers: Apigenin (LC laboratories), Baicalein (Indofine Chemical Company, 
Hillsborough, NJ), Curcumin (Sigma), Cyclopamine (Toronto Research Chemicals and 
LC Laboratories), EGCG (Sigma), Genistein (Sigma), Quercetin (Sigma), Resveratrol 
(Sigma).  
Mouse recombinant Shh was obtained from R&D Systems (Minneapolis, MN) cat. # 464-
SH. All compounds were dissolved in DMSO, except: LC Lab cyclopamine was 
dissolved in ethanol; Shh was dissolved in PBS with 0.1% BSA. In each experiment the 
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controls and all the treatments contained all vehicles used. All treatments were conducted 
in phenol red-free medium with charcoal-stripped serum.  
 
Protein Assay: 
All compound treatments for the growth assessment consisted of a 72-hour time course in 
phenol red-free RPMI 1640 medium, supplemented with 10% charcoal-stripped FBS. 
Cells seeded in 12-well plates and adjusted to phenol-red free medium for 24 hours. 
TRAMP-C2 cells were treated at 30-40% confluency, PC3 cells at 50%, which allowed 
the controls to reach 100% by day 3. Cells were lysed with 1N NaOH and left overnight. 
Protein assays to measure overall cell protein concentration were performed using Bio-
Rad Dc kit (Bio-Rad, Hercules, CA), with absorbance measured at 750 nm. Compounds 
were used at concentrations ranging from 1μM to 100μM in half log increments. Each 
experiment was performed at least three times in duplicate. Total cellular protein 
correlates well with thymidine uptake in prostate cancer cells and is a reliable assay to 
measure cell growth (111). 
 
RNA isolation: 
Total RNA was isolated from the TRAMP-C2 and PC3 cell line using the RNeasy kit 
(QIAGEN, Valencia, CA). From 1-5x 10
6
 cells we obtained between 25-35μg total RNA. 
RNA concentration was determined using the ND 1000 Spectrophotometer v3.1, 
NanoDrop Technologies (Wilmington, DA). RNA integrity was monitored on a 1% 
agarose gel.  
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RT-PCR: 
700ng of RNA was used in each RT-PCR reaction. RT-PCR was performed using the 
SSIII one-step RT-PCR system from Invitrogen with the following primers: Mouse 
GAPDH forward 5’-agcctcgtcccgtagacaaaat-3’; reverse 5’-ccgtgagtggagtcatactgga-3’, 
mouse Shh forward 5’-gtgagctttggattcatagtagacc-3’; reverse 5’-aattacaaccccgacatcatattta-
3’, mouse Gli1 forward 5’-aggaggaaagagagatccttcagt-3’; reverse 5’-
agtcaatagctatagtgagccatgc-3’, mouse Gli2 forward 5’-gttcacacacatatggcttctctc-3’; reverse 
5’-catcatatcaacaatgaacacatcc-3’, mouse Gli3 forward 5’-tctcattggaatgtgttctgtttt-3’; reverse 
5’-cattcatggagaaaagaaggagtt-3’. The following program was used for the reverse 
transcription and amplification: 55˚C for 30 min., 94˚C for 2 min., followed by 31 
(GAPDH), 35 (Gli1 and Gli3), or 40 (Shh and Gli2) cycles of 94˚C for 15 sec., 58˚C 
(GAPDH, Gli1 and Gli3) or 55˚C (Shh and Gli2) for 30 sec., 68˚C for 1 min., followed 
by the final extension step of 68˚C for 5 min. 
 
Real Time RT-PCR: 
Relative expression of mRNA was measured by one-step real-time RT-PCR with 
TaqMan EZ-RT-PCR kit (Applied Biosystems) on the Applied Biosystems 7500 Real-
Time PCR System. Real-time RT primers and probes were designed using the Primer 
Express software (Applied Biosystems). The candidate primers were verified using RT-
PCR. Mouse GAPDH: forward 5’- cagagacggccgcatctt-3’, probe 6FAM-
ttgtgcagtgccagcctcgtcc-TAMRA, reverse 5’-ccgaccttcaccattttgtctaC-3’. Mouse Gli1 
forward 5’-gcatgggaacagaaggactttc-3’, probe 6FAM-tgcccttttgccaccaagcca –TAMRA, 
reverse 5’-ccctgggaccctgacataaa-3’. Mouse Patched1: forward: 5’-
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ccctaacaaaaattcaaccaaacc-3’, probe 6FAM-tgatgtggcccttgttttgaatggtg-TAMRA, reverse 
5’-gcatatacttcctggataaaccttgac-3’. Human GAPDH: forward 5’-atggaaatcccatcaccatctt-3’, 
probe 6FAM-cgccccacttgattttgg-TAMRA, reverse 5’-caggagcgagatcc-3’. Human Gli1: 
forward 5’-gcaggtgcgtcttcaggttt-3’, probe 6FAM-cgaggcgtgagtatgacttccggc-TAMRA, 
reverse 5’-gccacacaagtgcacgtttg -3’. Human Patched1: forward 5’-gggtggcacagtcaagaaca-
3’, probe 6FAM-cgtcagcgcccatgccctg-TAMRA, reverse 5’-gggagtcattaactggaacatggt -3’.  
The relative expression of mRNA was measured by one-step real-time RT-PCR with 
TaqMan EZ-RT-PCR kit (Applied Biosystems) on the Applied Biosystems 7500 Real-
Time PCR System using the following program: 2 min at 50˚C, 30 min at 60˚C, 5 min at 
95˚C, followed by 45 cycles of 20 sec. at 94˚C and 1 min. at 62˚C. 
Each reaction was performed in triplicate for at least 3 individually isolated RNA 
samples per treatment. Data were analyzed using the CT method (396). 
 
Reporter Assay: 
Gli activity in the Shh Light II cell line was assayed after 24 hours or 48 hours of 
treatment with selected compounds in phenol red-free DMEM supplemented with 0.5% 
charcoal-stripped serum using the Dual-Luciferase Reporter Assay System (Promega 
Madison, WI). Each experiment was performed at least in triplicate. 
 
Western Blot Analysis: 
Cells were lysed using passive lysis buffer (Epitomics), scraped on ice, sonicated or 
passed through a 26G needle and spun for 30 min at 13K rpm at 0˚C. Cell lysates were 
collected and stored at -80˚C. Mouse prostates were disrupted in liquid N2 or using a 
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tissue homogenizer in TEG buffer. Tissues were spun for 10 min at 1.2K rpm at 4˚C, 
lysates were spun again for 30 min at 13K rpm at 0˚C. Tissue lysates were collected and 
stored at -80˚C. 
Rabbit polyclonal antibody against mouse Gli1 (ab7523, 1:2000, Abcam, Cambridge, 
MA discontinued and, Q59214R, 1:2000, Biodesign, Saco, MA), and against β-actin (C4-
HRP, 1:10
5
 Santa Cruz Biotechnology, Santa Cruz, CA) were used according to 
manufacturer’s recommendations. Western blot bands were scanned to Adobe Photoshop.  
 
Statistical Analysis:  
GraphPad Prism 4 was used to calculate p-values (http://www.graphpad.com). 
In vivo studies were analyzed with the chi-square test, comparing each treatment vs. 
control diet for each cancer stage. In vitro results were analyzed using the t-test. A p-
value <0.05 was considered statistically significant. 
 
Results: 
Botanical Compounds inhibit TRAMP-C2 cell growth.  
All 7 botanical compounds tested were able to inhibit mouse prostate cancer cell 
growth in the TRAMP-C2 cell line with IC50 values between 20-30μM (Table III-1). 
Compounds were used at concentrations ranging from 1 M to 100 M in half log 
increments. The maximal inhibition varied between 25% and 70%, with genistein 
showing the strongest effect followed by cyclopamine > curcumin = resveratrol > 
quercetin > EGCG > baicalein > apigenin. The inhibition of total cellular protein by 
genistein is significant starting at concentrations as low as 1μM.  
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Botanical Compounds decrease basal and Shh-stimulated Gli1 mRNA in TRAMP-
C2 cells. 
The botanical compounds were able to inhibit hedgehog pathway signaling as 
measured by real-time RT-PCR analysis of basal Gli1 mRNA concentrations in TRAMP-
C2 cells after a 24 and 72 hour treatment (Figure III-4 and Table III-1). Resveratrol had 
the strongest potency, with an IC50 value <1μM, followed by apigenin, baicalein and 
cyclopamine. Curcumin had the highest efficacy, reaching maximal inhibition of 95%, 
followed by cyclopamine with 85%. Baicalein and resveratrol produced the smallest 
change in Gli1 concentrations, with 35% maximal inhibition at 30μM and 10μM, 
respectively.  
The IC50 values for Gli1 inhibition were in each case lower than the IC50 value for 
growth inhibition, potentially indicating that inhibition of multiple pathways in addition 
to the Hh signaling pathway is needed to alter cell growth. We and others have reported 
previously that the 7 botanical compounds are able to act on other non-hedgehog 
signaling pathways (111). All compounds are also able to decrease Gli1 protein 
concentrations in TRAMP-C2 cells after a 24 hour treatment (Figures III-4C and III-5). 
 
It has been reported that there is a requirement for functional primary cilia for the 
hedgehog pathway to be active (289). In culture however, cells will not develop a 
primary cilium until they become confluent (397). We thus performed a time course 
experiment with cyclopamine and genistein, starting with cells that were already 
confluent. Since the data showed that all seven compounds inhibited cell growth, we 
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analyzed the Hedgehog pathway to determine if the inhibition was an apparent secondary 
effect and simply due to reduced cell confluency. Beginning near 100% confluency and 
investigating the cells after 2, 4, 8, 24 and 72 hour time points, we were able to observe a 
quick inhibition of hedgehog activity thus excluding the possibility of an indirect growth 
retardation effect of the compounds. 30μM cyclopamine was able to cause a significant 
decrease in Gli1 mRNA concentration after only 2 hours of treatment. 50μM genistein 
decreased Gli1 mRNA significantly after 4 hours (Figure III-6). These results confirm 
the relatively fast-acting hedgehog inhibitory ablility of genistein is independent of 
growth and a subsequent change in cilia or cell confluency. 
 
We next tested whether Gli1 mRNA expression in the TRAMP-C2 cell line could 
be increased with the pathway agonist Sonic Hedgehog. Treatment of TRAMP-C2 cells 
with 0.5μg/mL N-terminal Shh peptide caused a 25fold elevation in Gli1 mRNA that was 
inhibited by 3μM cyclopamine. 5μM genistein was able to reproducibly decrease this 
stimulated Gli1 mRNA (Figure III-5). 
 
Botanical Compounds decrease Shh-stimulated Gli-reporter activity in Shh Light II 
cells. 
To independently confirm the hedgehog inhibitory effects of the seven botanical 
compounds hown in Table III-10, we tested them in the widely used hedgehog 
responsive fibroblast cell line Shh Light II (395, 398). Four of the 7 compounds were 
able to decrease Shh peptide-stimulated Gli-reporter activity. The cyclopamine positive 
control had the strongest effect at 30μM, followed by curcumin, EGCG, genistein, and 
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resveratrol. Apigenin, baicalein and quercetin, were not able to inhibit the pathway in this 
system (Figure III-8).  
 
To test the general significance of our observations, we selected genistein, based 
on cost, availability and purity, to analyze further its functionality in a human prostate 
cancer cell line – PC3. Genistein can significantly inhibit PC3 growth starting at 10μM 
(Figure III-9A), with an IC50 of 40μM. At 10μM genistein is also able to significantly 
inhibit Gli1 and Patched1 mRNA concentrations in the cells by over 50% (Figure III-
9B).  
 
Botanical Compounds prevent tumorigenesis in TRAMP mice.  
Due to economical reasons we were not able to test each compound individually. 
For these initial studies the compounds were grouped based on their structure. The non-
flavones/non-isoflavones – curcumin and resveratrol plus EGCG were used together in 
Pure 3 Diet. The flavones/isoflavones - apigenin, baicalein, genistein and quercetin, were 
used together in Pure 4 Diet (Figure III-10). To examine the combined effects, all 7 pure 
compounds were used in the Pure 7 Diet. To further explore a natural exposure to these 
compounds, crude plant materials or extracts from which the pure compounds were 
derived were combined in the Crude 7 Diet. Saw palmetto, another prostate herbal was 
chosen in lieu of Scutalaria baicalensis because of initial difficulties in obtaining the 
latter. 
We tested the combinations of compounds used in the diets in vitro in the 
TRAMP-C2 cells, with concentrations of each individual compound low enough to where 
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no significant inhibition of Gli1 mRNA is seen. When combined, all mixes used result in 
significant reduction of Gli1 mRNA (Figure III-11). Synergistic effects of some of these 
compounds have been reported previously in prostate cancer cell lines (399).  
TRAMP mice fed the experimental diets grew similarly and consumed similar 
amounts of each diet throughout the study (Figure III-12). No group weight mean varied 
more than 7% from overall weight mean. After 5 months, prostates were staged 
according to severity of lesions (376). At this age, no normal prostates were seen, as 
observed with earlier studies, and a wide range of cancer stages was present. The relative 
incidence hyperplasia (HYP), prostatic intraepithelial neoplasia (PIN), well differentiated 
carcinoma (WDC), moderately differentiated carcinoma (MDC) and poorly differentiated 
carcinoma (PDC) were quantified by histological examination by a trained Veterinary 
Pathologist who was blinded to the treatments. All experimental diets significantly 
decreased cancer incidence, defined as WDC, MDC and PDC when compared to control 
diet (Table III-2). Within the specific cancer stages, all diets decreased WDC incidence 
in the TRAMP mice, with Pure 4 Diet (apigenin, baicalein, genistein and quercetin), and 
Crude 7 Diet having the strongest effect (Table III-3).  No protective effects were 
observed in ERαKo mice. 
 
Discussion 
In the fall of 2004 four papers were published that profoundly altered the outlook 
for prostate cancer treatment (303, 335, 337, 339). The authors independently reported 
that advanced human prostate cancer specimens, and metastases showed elevated 
Hedgehog pathway activity. These studies found that the Smoothened-binding and –
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inhibiting compound, cyclopamine, an alkaloid isolated from Californium veratrum, was 
able to inhibit human prostate cancer cell proliferation in vitro and was able to cure 
mouse xenograft models of prostate cancer (303, 337, 339, 400). 3-4 weeks of high dose 
cyclopamine injections caused tumor regression without reoccurrence after cessation of 
treatment. Thus, cyclopamine is potentially a promising treatment for prostate cancer. 
However, the high cost of cyclopamine make it an unrealistic drug for wide scale use 
(401). Several companies are working to develop small molecule hedgehog pathway 
antagonists, some of which are now entering phase 2 clinical trials.  
 
We were interested in testing cyclopamine in our TRAMP mice, to see whether it 
is able to cure SV40 T/t antigen induced prostate tumors in vivo. Unfortunately, the price 
and availability of cylopamine at the time made it impossible to conduct extensive animal 
studies. Our previous investigations revealed that several botanical compounds that 
inhibit prostate cancer cell proliferation in vitro (111) when used in the diet, also delayed 
prostate cancer incidence in vivo in TRAMP mice (Table III-2). Since there are many 
known possible mechanisms of action for botanical compounds potentially useful as 
cancer preventative agents, we decided to test the hypothesis that these selected seven 
compounds, that were able to reduce cancer incidence in our TRAMP mice, would have 
the ability to inhibit Hedgehog signaling. We found that all 7 botanical compounds had 
cancer preventative action when fed in combination to TRAMP mice. There was a 
significant reduction in overall cancer incidence, with significant effects at the well 
differentiated carcinoma stage with the Pure 4 and Crude 7 Diet (Table III-2 and III-3). 
After obtaining these results with our combination diets the Lubahn lab will further test 
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some of the compounds individually. Genistein (355, 356, 402), EGCG (191, 403-408), 
resveratrol (260), and apigenin (113), and recently curcumin (172) have all been 
previously tested individually, and only high dose genistein (250-500mg/kg) (356) has 
been reported to effect PDC. Thus we will further test cyclopamine, along with curcumin 
and genistein as treatments for already established tumors in TRAMP mice. 
We were very interested in testing the effects of the 7 compounds on hedgehog 
signaling in vitro and in vivo. For our in vitro studies we used the TRAMP-C2 cell line 
derived from a primary prostate tumor of a 32-week old TRAMP mouse (88) to study the 
mechanism of action of those compounds, as well as the Shh Light II cell line. Our results 
show that four of seven compounds, namely genistein, curcumin, EGCG, and resveratrol, 
inhibited the Hedgehog-signaling pathway in our assays comparable to the control 
compound cyclopamine. 
 
Why did not all seven compounds work in both these in vitro hedgehog 
assays?  
Each of the 7 compounds inhibited prostate cancer cell growth in both human and 
in mouse cell lines. It was however interesting to see the discrepancy in hedgehog 
pathway inhibition between Gli1 mRNA inhibition in TRAMP-C2 cells and Gli-reporter 
activity in Shh Light II cells. Three out of seven compounds – apigenin, baicalein, and 
quercetin, inhibit strongly, even at low concentrations Gli1 mRNA. However, in Shh 
Light II we could not observe any inhibition with concentrations as high as 30μM with 
apigenin, baicalein or quercetin.  
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Potential reasons these three compounds are not inhibiting the hedgehog-signaling 
pathway in both assays could be due to their direct vs. indirect effects on the pathway, 
with the possibility of cell specific characteristics from additional unknown pathways’ 
crosstalk with the hedgehog pathway. For example, in melanomas interactions between 
Gli1 and the Ras-MEK/AKT pathways have been observed (409). Finally, a recent report 
presents data that in some cell lines hedgehog pathway activation at the level of Gli1 and 
Gli2 can be inhibited by TGF- inhibitors, but not by cyclopamine (410).There are many 
significant steps between the hedgehog signal at the cell membrane and the Gli-regulated 
transcription response in the nucleus, with a variety of potential signaling interactions not 
yet fully explored. Also, all of the targets of botanical compounds have not been 
completely determined. Genistein for example, which has been the most extensively 
studied, regulates a large range of molecular and enzymatic activities which may interact 
with hedgehog signaling (see chapter I).  
The changes in enzyme activities could differentially alter an endogenous 
inhibitor that is absent in one of the cells, or the different media used to culture the two 
cell lines could impinge on a hedgehog crosstalking pathway. Potential candidates for 
such inhibitors or modulators are cholesterol derivatives and precursors whose 
concentrations vary widely between cell types and culture media, and which can be 
removed with different efficiencies by charcoal-stripping sera. We are using charcoal-
stripped media for all our treatments, with the charcoal removing most cholesterol 
compounds, like hedgehog activating oxysterols (307, 411), or sex steroids, like 
androgens, which also have been shown to inhibit hedgehog signaling in prostate cancer 
(412, 413). 
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Crosstalk with the hedgehog-signaling pathway is still under active investigation, 
and there are still open questions regarding good models for studying the pathway. 
Tumors from TRAMP mice and TRAMP-C2 cells clearly demonstrate Hedgehog 
signaling which makes them appropriate for studying prostate cancer responses to 
hedgehog antagonists. It had been proposed that tumor cells of epithelial origin, would 
not have a functional autocrine hedgehog signaling (414, 415), our TRAMP-C2 cells, 
however, show hedgehog signaling that is both inducible and inhibitable (Figure III-5).  
 
All of our in vitro cell culture experiments have been conducted with cells of 
epithelial origin. By the current dogma, Hedgehog signaling consists of communication 
between different cell types. The ligand (Hh) is produced by epithelial cells at 
mesenchymal interfaces and signals to the adjacent mesenchyme through its receptor 
Patched. (281, 416, 417). Many cancer cells however undergo an epithelial-mesenchymal 
transition with cancer progression, which could be what we are seeing in our cells. While 
Zhang et al. (418) showed a lack of demonstrable autocrine hedgehog signaling in human 
prostate cancer cell lines,  we have observed cyclopamine inhibiting PC3 and LNCaP cell 
growth (data not shown), as well as decreased Gli1 and Patched1 mRNA in PC3 cells by 
genistein (Figure III-9B). These differences in observation might be due to higher 
starting confluencies (419), or different components in the medium. We are using 
charcoal-stripped media for all our treatments, with the charcoal removing most 
cholesterol compounds, like hedgehog activating oxysterols (307, 411), or sex steroids, 
like androgens, which have been shown to inhibit hedgehog signaling in prostate cancer 
(412, 413, 420). 
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We also looked for hedgehog pathway activation in TRAMP mice on different 
backgrounds. We saw a higher Gli1 mRNA and protein concentration in primary tumors 
from C57/FVB crosses compared to pure C57JBL6 (data not shown). This agrees with 
the observation, that FVB mice and C57/FVB crosses are more prone to metastasis than 
C57, and hedgehog pathway activity being greatly elevated in metastases relative to 
primary tumors. Interestingly, C57BL6 mice carry a Patched polymorphism when 
compared to FVB mice. This polymorphism makes them highly resistant to development 
of skin squamous carcinomas (421).  
 
The LADY model is an alternative prostate cancer model to TRAMP. Gipp et al. 
reported a lack of increased hedgehog signaling markers during tumor development in the 
transgenic LADY prostate cancer mouse model (422). The LADY mice have been 
created using the androgen-regulated probasin driving the large T antigen on a CD-1 
background. Although the tumors are very fast growing they rarely produce metastases 
(423). The lack of metastatic potential might be explained by the low hedgehog activity 
in this model, and stress the importance of strain background for studying the Hh 
signaling pathway. 
Lu Yuan in the Lubahn lab recently sequenced the Patched gene from CD-1 mice 
to test for the cancer/metastasis resistance polymorphism, and surprisingly CD-1 carry 
the wild type allele, like FVB, so our hypothesis stating that the lack of hedgehog activity 
in the LADY model could be explained by the less aggressive mutant Patched allele was 
incorrect.  
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The SV40 large/small T antigen disrupts the actions of Rb and p53. Since both the 
TRAMP tumors and the TRAMP-C2 and Shh Light II cells express the T antigens, it is 
interesting to note, that mutations in p53 occur frequently alongside mutations in the 
Hedgehog signaling pathway. Their effects tend to be additive making animals more 
susceptible to cancer (424). There has been a recent report on a regulatory loop between 
p53 and Gli1 that has to be evaluated in regard to our model (425). 
p53 mutations are seen frequently with Patched mutations in basal skin cancer (426, 427). 
On the other hand, Gli-induced skin (428) and gastric (429) tumors have wildtype p53, 
suggesting that Gli1 is sufficient in tumor initiation, and does not require additional p53 
mutations. Constitutively activated mutants of Smoothened, which causes over-
expression of Gli1 and Gli2, have been shown to inhibit the accumulation of the tumor 
suppressor protein p53 (430). It has been recently reported that p63 and p73, but not p53, 
over-expression can induce Shh expression (431). 
 
We have analyzed tumors for TRAMP mice for Gli1 mRNA and Gli1 protein by 
western blot and so far we have observed a high variance in Gli1 expression among and 
within treatments (Figure III-13). This could be due to the nature of our sample material, 
since PDC tumors tend to be non-homogenous and may contain large necrotic areas. We 
are planning to perform immuno-histochemical analysis on the tissues as soon as a lot-to-
lot consistent Gli1 antibody becomes available in larger quantities.  
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The doses of our botanical compounds shown to be effective in vitro are at 
apparent pharmacological levels. However, reports on free genistein levels (aglycone) in 
serum and prostate of rats fed genistein diets vary. Dalu et al. (432) reported bioavailable 
genistein to be comparable between serum and dorsolateral prostate in Lobund-Wistar 
rats fed 250mg/kg and 1g/kg genistein diets at ~18 and 150nM, respectively. Chang et al. 
however reported higher concentrations of aglycone genistein in several tissues including 
the prostate compared to serum (433).  In their hands, Sprague-Dawley Rats fed 
100mg/kg and 500mg/kg genistein diets reached prostate concentrations of bioavailable 
genistein as high as 400 and 500nM, compared to 6-30 and 60-300nM in serum, 
respectively. These values are already in the range of genistein’s effect on prostate cancer 
cell growth inhibition and Gli1 mRNA reduction in TRAMP-C2 cells, which were 
significant, starting at 100nM. Thus, dietary concentrations may be sufficient to reach at 
least partial hedgehog inhibition because of the ability of prostates to concentrate some 
compounds.  
 
In our in vivo study with TRAMP mice three of the 7 compounds, curcumin, 
EGCG and resveratrol, were present in Pure 3 Diet which showed an over 50% reduction 
in PDC incidence (Table III-3), which is not significant due to the small number of 
animals displaying PDC. We have seen that low doses (300mg/kg) of genistein 
significantly reduce WDC incidence (data not shown), while high doses (500mg/kg) of 
genistein have been reported to decrease PDC incidence in TRAMP mice (356). These 
four compounds potentially are strong alternatives to cyclopamine. They are significantly 
cheaper and safer, and have been used in traditional diets and in dietary supplements, that 
are available in the US. 
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Although the compounds have been extensively used, there only has been a 
limited number of reproductive safety studies conducted, that would shed light on the 
potential teratogenicity of those compounds indicating a cyclopamine-like effect. 
Genistein did not cause any fetal malformations when fed to pregnant rats up to 
1000mg/kg/day (434). Resveratrol has been reported to act as a anti-teratogenic 
compound (435), as well as curcumin (175, 436). Feeding pregnant rats diets 
supplemented at 14,000 ppm EGCG during organogenesis was non-toxic to dams or 
fetuses (437). 
 
 Our findings of hedgehog inhibition with genistein, curcumin, EGCG and 
resveratrol potentially provide available, safer and more affordable anticancer treatments, 
in hedgehog-signaling-driven cancer types. Additionally, they help provide better 
understanding of the mechanisms by which traditional herbal medicines and dietary 
supplements may be working to prevent and treat cancers. 
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Figure III-1: TRAMP mice express Gli transcription factors.  
 
Both strains of TRAMP used in the lab, the C57 and the F1 cross FVB/C57 mice express 
Gli1 and Gli3 mRNA as determined by RT-PCR (A), and Gli1 protein as determined by 
western blot by Dr. Mary Sakla (B). The FVB/C57 cross, which is more aggressive and 
more susceptible to metastasis has a higher expression of Gli1, the positive pathway 
executor, and a lover expression of Gli3 which is acting as a repressor. 
Gli1 protein 
C57    FVB/C57 C57            FVB/C57 
Gli1    Gli3 GAPDH  Gli1   Gli3   GAPDH 
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Figure III-2: TRAMP-C2 cells express Hedgehog pathway components. 
 
TRAMP-C2 pathways express Gli1, Gli2, Gli3, and Shh mRNA as shown by RT-PCR. 
GAPDH 
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Botanical IC50  Maximal Gli1 inhibition  
Apigenin < 10μM 60% at 30μM 
Baicalein < 10μM 35% at 30μM 
Curcumin* 10-20μM 95% at 100μM 
Cyclopamine 3-10μM 85% at 30μM 
EGCG 10-25μM 80% at 100μM 
Genistein 20μM 75% at 50μM 
Resveratrol < 1μM 35% at 10μM 
Quercetin* 10μM 55% at 30μM 
* 24 hours 
 
Table III-1: Botanical compounds inhibit Hedgehog pathway activity in TRAMP-C2 cells. 
Gli1/GAPDH mRNA concentrations indicating Hedgehog pathway activity after 72 or 24 hours 
of treatment with various botanicals were determined by real-time RT-PCR. 
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Diet N 
Phenotype 
Non-Cancer Cancer 
Casein 22 3 (13.6%) 19 (86.4%) 
Pure 3 20 10 (50%) 10 (50%)* 
Pure 4 18 12 (66.7%) 6 (33.3%)*** 
Pure 7 19 11 (57.8%) 8 (42.2%)** 
H-Casein 20 5 (25%) 15 (75%) 
H-Crude 7 21 15 (71.4%) 6 (28.6%)** 
 
Table III-2:  Incidence of prostate tumorigenesis in TRAMP mice fed various botanical 
compounds.  
Male TRAMP mice were started on diets at weaning, and sacrificed at 5 months.  
Pure 3 = Curcumin + Resveratrol + EGCG 
Pure 4 = Apigenin + Baicalein + Genistein + Quercetin 
Pure 7 = Pure 3 + Pure 4 
Crude 7 = Soy + sencha leaves + tumeric + yucca roots + saw palmetto + chamomile flowers + 
gingko; H-mice were heterozygous for ER α.  
Non-cancer defined as normal, hyperplasia, and prostatic intraepithelial neoplasia. 
Cancer defined as well-, moderately-, and poorly differentiated carcinoma. 
* p-value<0.05; **p-value<0.01; ***p-value<0.001; 2 – test was performed to compare cancer 
vs. non-cancer incidence for each treatment vs. casein diet. 
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Genotype Diet N 
Phenotype 
Non-Cancer Cancer 
Normal  HYP PIN WDC MDC PDC 
ERWT 
Casein 
22 0 1 (4.5%) 2 (9%) 14 (63.6%) 0 5 (22.9%) 
ERαKO 18 0 0 4 (22%) 14 (78%) 0 0 
ERWT 
Pure 3 
20 0 2 (10%) 8 (40%)* 8 (40%) 0 2 (10%) 
ERαKO 19 0 0 4 (21%) 15 (79%) 0 0 
ERWT 
Pure 4 
18 0 8 (44.5%)** 4 (22.2%) 2 (11.1%)** 0 4 (22.2%) 
ERαKO 20 0 1 (5%) 4 (20%) 14 (70%) 0 1 (5%) 
ERWT 
Pure 7 
19 0 0 11 (57.8%)** 5 (26.3%)* 0 3 (15.9%) 
ERαKO 19 0 0 1 (5%) 14 (74%) 1 (5%) 3 (16%) 
 
ERαH 
Casein 20 0 0 5 (25%) 10 (50%) 0 5 (25%) 
Crude 7 21 0 0 15 (71.5%)* 2 (9.5%)* 0 4 (19%) 
 
Table III-3: Incidence of prostate tumorigenesis in TRAMP mice fed various botanical 
compounds for each tumor stage. 
Male TRAMP mice were started on diets at weaning, and sacrificed at 5 months.  
Pure 3 = Curcumin + Resveratrol + EGCG 
Pure 4 = Apigenin + Baicalein + Genistein + Quercetin 
Pure 7 = Pure 3 + Pure 4 
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Crude 7 = Soy + sencha leaves + tumeric + yucca roots + saw palmetto + chamomile flowers + 
gingko; H-mice were heterozygous for ER α.  
χ2 – test was performed for each treatment relative to control diet within each tumor stage. * p-
value<0.05; **p-value<0.01. 
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Figure III-3: Botanical compounds inhibit TRAMP-C2 cell growth.  
Mouse prostate cancer cell growth was determined based on total protein concentration after a 72 
hour treatment with each compound relative to control treatment. Compounds were used at 
concentrations ranging from 1μM to 100μM in half log increments, genistein was tested down to 
100pM Each experiment was performed at least three times in duplicate
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Figure III-4: Botanical compounds inhibit Hedgehog pathway activity in TRAMP-C2 cells. 
Relative Gli1 mRNA concentrations after 72 hours of (A) cyclopamine and (B) genistein 
treatment as determined by real-time RT-PCR. GAPDH was used as control. (C) Gli1 protein 
decreases after 24 hours of treatment with cyclopamine and genistein (here: Biodesign antibody).  
T-test was performed to determine p-value. * p<0.05, error bars indicate SD. 
 
C 
B A 
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Figure III-5: Botanical compounds decrease Gli1 protein in TRAMP-C2 cells.  
Representative western blot of TRAMP-C2 cell lysates analysed for Gli1 (here: Biodesign 
antibody) and β-actin after a 24 hour treatment with 3μ cyclopamine and 10μM of all other 
botanicals.  
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Figure III-6: Gli1 mRNA in TRAMP-C2 cells by real-time RT-PCR after time course 
treatments with cyclopamine and genistein. 
Sub-confluent TRAMP-C2 cells were treated with 50μM genistein or 30μM cyclopamine. RNA 
was isolated after 2, 4, 8, 24, and 72 hours. Gli1 mRNA was measured relative to GAPDH 
mRNA. Each experiment was performed in triplicate. T-test was performed to determine p-
value. * p< 0.05, error bars indicate SD. 
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Figure III-7: Shh can stimulate Gli1 mRNA concentrations in TRAMP-C2 cells, genistein 
can inhibit the stimulated Gli1 expression.  
TRAMP-C2 cells were treated with mouse recombinant 0.5μg/mL Shh for 24 hours. Co-
treatment with 5μM genistein resulted in significant reduction of Gli1 mRNA concentrations. 
Shh stimulation varied significantly between experiments. Insert shows genistein inhibition of 
Shh-stimulated Gli1 expression normalized to 0.5μg/mL Shh-stimulated state within individual 
experiments, since the stimulation by Shh varied between 3-8 fold between experiments.  
T-test was performed to determine p-value. * p<0.05, error bars indicate SD. 
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Figure III-8: Botanical compounds inhibit Shh-stimulated Gli-responsive promoter in Shh 
Light II cell line. 
Shh Light II cells were treated with various compounds in full medium supplemented with 0.5% 
FBS in the presence of 1μg/mL Shh for 24 hours before cells were lysed and subjected to 
luciferase assay to assess the regulation of the Gli-responsive promoter. Each experiment was 
performed at least in triplicate. T-test was performed to determine p-value. * p<0.05, error bars 
indicate SD. 
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Figure III-9: Genistein inhibits cell growth and Hedgehog pathway activity in PC3 cells. 
 101 
(A) Total protein after 72 hours genistein treatment. (B) Gli1 and Patched1 mRNA 
concentrations after 72 hours genistein treatment as determined by real-time RT-PCR. GAPDH 
mRNA was used as control. Each experiment was performed at least in triplicate. T-test was 
performed to determine p-value. * p<0.05, error bars indicate SD. 
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Figure III-10: Structures on botanical compounds used in mouse diets. 
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Figure III-11: Botanicals act synergistically to inhibit Gli1 mRNA in TRAMP-C2 cells. 
TRAMP-C2 cells were treated for 24 hours with selected botanical or mix of botanicals. Total 
RNA was assayed for relative Gli1 mRNA concentration changes.  
Mix 3 = Curcumin + Resveratrol + EGCG 
Mix 4 = Apigenin + Baicalein + Genistein + Quercetin 
Pure 7 = Pure 3 + Pure 4 
Each experiment was performed twice in triplicate. * p-value<0.05 (T-test) 
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Figure III-12: Total body weights of mice at the end of study.  
Pure 3 (p= 0.0164) and Pure 7 (p=0.0003) were statistically lower than casein control mice. No 
group mean varied more than 7% from total mean. 
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Figure III-13: Gli1 protein expression varies in prostates of TRAMP mice. 
Total cellular protein from frozen mouse prostates were analyzed by western blot assays with 
primary antibodies to Gli1 (biodesign), and β-actin (Santa Cruz). Each well was loaded with 
40μg protein. 
Gli1 
 
 
 
β-actin 
H
Y
P
 c
a
se
in
 
P
D
C
 c
a
se
in
 
 P
D
C
 m
ix
3
 
P
D
C
 m
ix
4
 
P
D
C
 p
u
re
7
 
H
Y
P
 
la
d
d
er
 
H
Y
P
/P
IN
/W
D
C
 
P
D
C
 c
a
se
in
 
P
D
C
 c
a
se
in
 
P
D
C
 m
ix
3
 
P
D
C
 m
ix
3
 
P
D
C
 m
ix
4
 
P
D
C
 m
ix
4
 
P
D
C
 p
u
r
e
7
 
P
D
C
 p
u
r
e
7
 
 106 
IV - Crosstalk between Estrogen- and Hedgehog Signaling Pathways 
 
Overview 
 
The botanical compounds, that we were testing as described in chapter III and that were 
able to inhibit hedgehog signaling in prostate cancer cell lines and partially in Shh Light II cells, 
all display estrogenic actions. They were either reported to bind to the estrogen receptors and/or 
act as an agonist/antagonist in functional assays. I was thus interested to test our hypothesis that 
these compounds were acting through one or both of the estrogen receptors, and further test how 
classic estrogens and antiestrogens would affect the hedgehog pathway. 
  
 17β-estradiol was able to inhibit Gli1 mRNA and protein in TRAMP-C2 cells. It was also 
able to decrease Sonic Hedgehog- and Smoothened Agonist (SAG)-induced Gli-reporter activity 
in Shh Light II cells in a dose-dependent manner. Surprisingly, the pure ER antagonist ICI was 
also able to inhibit Gli1 mRNA in the TRAMP-C2 cells.  
 Further indications for estrogenic regulation of hedgehog signaling could be 
demonstrated through ERβ-binding oxysterols that were able to induce Gli1 mRNA in TRAMP-
C2 cells. 
 Differential inhibition of Shh- vs. SAG-induced Gli-reporter activity by 17β-estradiol and 
EGCG suggests a possible target for these at a step in the pathway between the Shh-binding 
Patched and SAG-binding Smoothened (see Working Model Figure IV-10). 
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Introduction 
There have been a variety of publications suggesting some crosstalk between hedgehog-
signaling and estrogen-signaling pathways. Estrogen influences hedgehog signaling in the 
thymus, where estrogen deficient Aromatase KO mice displayed impaired thymocyte 
development and displayed increased Smoothened expression (438). Estrogenization of neonatal 
rat prostates differentially altered expression of various hedgehog proteins in the pathway, 
specifically decreasing Shh, Patched, Gli1and 3 expression, which caused a lobe specific 
blockage of ductal branching in the dorsal and lateral prostate (281). One of the ligands, Indian 
Hedgehog, is target of PR, which itself is ER regulated (439-441). 
Both, estrogen- and hedgehog-signaling pathways also share downstream targets, for 
example E-cadherin which is a target of the Hh pathway via Snail (442, 443), and is regulated by 
ER via MTA3 and Snail (443-445). However, regulation by estradiol was not observed in 
promoter studies with human sonic hedgehog (446). 
 
A recent connection appeared when two laboratories reported the cholesterol metabolites 
oxysterols as novel activators of the Hedgehog signaling pathway (307, 411). 
At the same time a different two laboratories published work on 27-Hydroxycholesterol, one of 
the oxysterols reported to activate hedgehog signaling, being an endogenous SERM (selective 
estrogen receptor modulator) (447, 448). These two oxysterol SERM papers report 
binding/response to ERs in the low micromolar range. In our lab, Nicholas Starkey and Sara 
Drenkhahn have found that 25- and 27-OHC in 
3
H-estradiol competition binding assays, bind 
ERβ 100x better than ERα, with a Kd of ~ 20nM (data not shown). 
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  Initially it was reported that oxysterols bind directly to Smoothened (307). Later, 
however, a different lab found that 20- and 22-OHC are probably not binding directly to 
Smoothened, or at least not to the same region as cyclopamine, since they were unable to 
displace BODIPY-cyclopamine from Smoothened as measure by a FRET assay (411). 
We hypothesize that oxysterols are binding to the missing link between Patched and 
Smoothened. Since oxysterols do not bind directly to Smoothened, there must be another 
oxysterol-binding protein between Patched and Smoothened – we propose it to be ERβ. 
 
Materials and Methods 
Chemicals and constructs: 
The purified compounds used in tissue culture experiments were obtained from the following 
suppliers: Apigenin (LC laboratories), Baicalein (Indofine Chemical Company, Hillsborough, 
NJ), Curcumin (Sigma), Cyclopamine (Toronto Research Chemicals and LC Laboratories), 
EGCG (Sigma), Genistein (Sigma), Quercetin (Sigma), Resveratrol (Sigma). Mouse recombinant 
Shh was obtained from R&D Systems (Minneapolis, MN) cat. # 464-SH. All compounds were 
dissolved in DMSO, except: LC Lab cyclopamine was dissolved in ethanol; Shh was dissolved 
in PBS with 0.1% BSA. In each experiment the controls and all the treatments contained all 
vehicles used. All treatments were conducted in phenol red-free medium with charcoal-stripped 
serum. 
GliBS-reporter was obtained from the ATCC.  
 
Cell culture 
TRAMP-C2 and Shh Light II cells were obtained from the ATCC (www.atcc.org). 
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HEK293 stably transfected with N-Shh were a kind gift from Dr. Beachy, HHMI, Stanford 
University.  
 
TRAMP-C2 cells were maintained in RPMI 1640 RPMI 1640 media supplemented to contain 
10% fetal bovine serum (U.S. Bio-Technologies, Parkerford, PA), 4.5g/mL Glucose, 4mM L-
glutamine , 100 M Non-essential Amino Acids, 10mM HEPES, 1mM Sodium Pyruvate, and 1% 
Penicillin/ Streptomycin (all from Invitrogen, Carlsbad, CA). 
 
Shh Light II cells (JHU-68) were maintained in Dulbecco's modified Eagle's medium 
supplemented with 10% NBCS, 0.4mg/mL G418, 0.15mg/mL zeocin, 4mM L-glutamine, 
HEPES, and adjusted to contain 1.5g/L sodium pyruvate. This mouse embryonal NIH 3T3 cell 
line contains a stably transfected luciferase  reporter with 8 copies of the consensus Gli binding 
site derived from the mouse Hepatocyte Nuclear Factor-3β (JHU-73 pGL3B/8XgliBS-lc-luc 5’-
GAACACCCA-3’) (395). The responsiveness of these cells to hedgehog activators and 
inhibitors is very sensitive. In order to maintain the ability to respond the cells need to be 
subcultured between 70%-80% confluency in a ratio not higher than 1:8. 50K and 100K 
cells/well were then seeded in 24-well plates and incubated for 72 hours in a pre-treatment 
medium (DMEM supplemented with maintenance medium w/o G418 or zeocin). At the time of 
treatment all of the cells are super-confluent, often forming multi-layered clusters. Cells are 
treated for 48 hours with selected compound in treatment medium (phenol-red free DMEM 
supplemented with 10% charcoal-stripped NBCS, HEPES, L-glutamine, and NaPyruvate) 
GliBS-reporter activity was assayed using the Dual Luciferase System, Promega. 
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HEK 293 N-Shh cells were maintained in DMEM, supplemented with 10% FBS, Pen/Strep, and 
G418 (Geneticin) 400 mg/ml. For preparation of conditioned medium, cells were seeded in 
150cm
2
 flasks and grown to ~80-90% confluency. Cells were washed with unsupplemented 
DMEM and supplemented with 35mL DMEM with 2% FBS, P/S, but NO geneticin. Cells were 
maintained for another 24-30 hours, medium was collected and passed through a 0.22μM filter. 
Conditioned medium was stored at -80°C for up to 6 months. 
 
RNA isolation and RT-PCR: 
Total RNA was isolated from the TRAMP-C2 cells using the RNeasy kit from QIAGEN. From 
1-5x 10
6
 cells we obtained between 25-35μg total RNA. RNA concentration was determined 
using the ND 1000 Spectrophotometer v3.1, NanoDrop Technologies. 700ng of RNA was used 
in each RT-PCR reaction. RT-PCR was performed using the SSIII one-step RT-PCR system 
from Invitrogen. The following primers were used: mouse GAPDH: forward 5’- 
cagagacggccgcatctt-3’, reverse 5’-ccgaccttcaccattttgtctac-3’. mouse ERα: (NM007956 coding 
redion 183-1982, 599aa) forward 576: 5’-gtgccctactacctggagaacgag-3’, reverse 793: 5’-
cagaccccataatggtagccagag-3’ (exon2-3, product size 128bp) and forward 1208: 5’-
tgaagcctcaatgatgggcttatt-3’, reverse 1665: 5’-ccatcaggtggatcaaagtgtctg-3’ (exon 5-8, product size 
458bp); mouse ERβ: (NM 010157, coding region 348-1997, 549aa and NM 207707, coding 
region 348-2051, 567aa) forward 1464: 5’-ctcatctttgctccagacctcgtt-3’, reverse 1736: 5’-
actcttcgaaatcacccagaccag-3’ (exon 5-8 ± 6, product size 273bp for NM 010157 and 327bp for 
NM 207707) and forward 1669: 5’-gtagccggaagctgacacacctat-3’, reverse 1959: 5’-
tactgtcctctgtcgagcagcact-3’ (exon 8-9, product size 291) Mouse uterus was used as positive 
control for ERα expression, mouse ovary for ERβ. The following program was used for the 
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reverse transcription and amplification: 55˚C for 30 min., 94˚C for 2 min., followed by 25-40 
cycles of 94˚C for 15 sec., 55˚C for 30 sec., 68˚C for 1 min., followed by the final extension step 
of 68˚C for 5 min. RT-PCR products were visualized on a 1% agarose gel with ethidium bromide 
staining and UV detection. 
 
Transfection assay 
GliBS-reporter (JHU-73) was obtained from the ATCC and independently from Dr. Reiter’s 
laboratory, UCSF. 2 clones from each construct, grown up in our lab, were used to confirm the 
results. TRAMP-C2 cells were seeded in 24-well plates in phenol-red free full medium 
supplemended with 10% charcoal-stripped FBS. Cells were transfected at 60-80% confluency 
with 500ng of GliBS-reporter, 10ng renilla, and 100ng GliBS-luciferase reporter or control 
vector. Cells were treated 24 hours after transfection, and assayed for luciferase and renilla 
activity after another 24 hours using the Dual Luciferase Assay from Promega.  
 
For real-time RT-PCR, western blot and luciferase reporter assays see chapter III. 
 
Results 
TRAMP-C2 cells express both estrogen receptors. 
TRAMP-C2 cells express both, ERα and ERβ, as determined by RT-PCR and western 
blot (Figure IV-1), and are therefore an appropriate model to study the effects of botanical and 
estrogenic compounds as mediated by estrogen receptors. 
 
 
 112 
Oxysterols stimulate Gli1 mRNA expression in TRAMP-C2 cells.  
20-, 22-, 25-, and 27-OHC are able to significantly increase Gli1 mRNA concentration in 
TRAMP-C2 cells after 24 hour treatments, comparable to the N-terminal Shh peptide and the 
Smoothened agonist SAG (Figure IV-3). This 2-8 fold stimulation of Gli1 obtained with 10μM 
of each compound in our mouse epithelial cell line is comparable to the ~10 fold stimulation by a 
mix of 5μM 20- and 22OHC reported in a pluripotent mesenchymal cell line – M2 (411). 
Genistein is able to inhibit the 25-, and 27OHC-induced stimulation of Gli1 mRNA (Figure IV-
4).  
 
Estrogen and antiestrogens inhibit Gli1 mRNA expression in TRAMP-C2 cells.  
To test whether the observed inhibition of Gli1 mRNA was possible through one of the 
estrogen receptors, we tested 17β-etradiol, which is binding and acting as an agonist with both 
estrogen receptors at comparable concentrations. 10nm E2 was able to significantly inhibit both 
Gli1 mRNA and Gli1 protein expression in TRAMP-C2 cells (Figure IV-5 and IV-6).  
 
In order to establish whether genistein exhibits its inhibitory action on the Hedgehog 
pathway via the estrogen receptor. I used the pure antiestrogen ICI to block both ERs and 
hopefully prevent genistein from inhibiting Gli1 mRNA. Surprisingly, at a high dose (1μM) ICI 
itself was able to significantly inhibit Gli1 mRNA, and has an additive effect in co-treatment 
with genistein. Also a lower dose of 100nM ICI which did not inhibit by itself was acting 
additive with genistein (Figure IV-5). 
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To determine which ER receptor is responsible for this inhibitory effect, I used the ERα 
specific agonist PPT, and the ERβ specific agonist DPN. At 10nM both compounds showed high 
variance in inhibitory actions, with PPT inhibiting significantly, and DPN having a not quite 
significant effect (Figure IV-5). 
 
GliBS reporter experiments yield surprising but suggestive results. 
To confirm the effects of the estrogens and phytoestrogens on the mRNA modulation of 
the hedgehog pathway TRAMP-C2 cells were transfected with a Gli Binding Site-luciferase 
reporter. Surprisingly, I was not able to stimulate this Gli reporter with either overexpression of 
mouse Gli1 or the Sonic Hedgehog ligand (Figure IV-7). Also cyclopamine, or any of the 
phytoestrogens, were not able to inhibit the Gli reporter, even though they were able to inhibit 
Gli1 mRNA (Table III-1 and Figure III-2) and Gli1 protein (Figure III-3) in the TRAMP-C2 
cells. The only significant effects were obtained with 25- and 27-OHC, and those were again 
opposite to what I have seen in real-time RT-PCR assays, since both compounds were inhibiting 
the reporter by ~50% (Figure IV-7). It is possible that the Gli1 protein, which is significantly 
higher expressed in TRAMP-C2 that it is, even in stimulated Shh Light II cells (western blot data 
not shown), is at its maximum. The less stable Gli1 mRNA is more responsive to both inhibition 
and stimulation, but the protein is not.  
 
In Shh Light II cells, which are expressing both estrogen receptors as determined by RT-
PCR (Figure IV-1), 17β-etradiol had no effects on the baseline reporter activity (data not 
shown), but had significant inhibitory effects on both, SAG- and Shh-conditioned medium (CM)-
stimulated GliBS-reporter activity, starting at 100pM (Figure IV-8).  
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When I tested the seven botanicals compounds from chapter III under the new 
stimulatory conditions (see materials and methods) with SAG and Shh-conditined medium used 
to stimulate the reporter, only baicalein, curcumin, and resveratrol were able to inhibit both Shh-
conditioned medium- and SAG-induced GliBS-reporter activity. Apigenin had no effect with 
SAG, and a stimulatory effect with CM. EGCG had a stimulatory effect with SAG, but strongly 
inhibited CM. Genistein had a greatly variable response depending on cell number (to be 
discussed later), but had overall no effect on pathway activity in this assay. Quercetin was 
slightly inhibitory with SAG, but had no effect with CM (Figure IV-9). 
 
Discussion: 
 We were able to confirm our hypothesis that estrogens and phytoestrogens are able to 
inhibit the hedgehog signaling pathway. We demonstrated that selected oxysterols which can 
bind ER could stimulate Gli1 mRNA expression in our mouse prostate cancer cell line (Figure 
IV-3), and that the observed stimulation was inhibitable by genistein (Figure IV-4). And since 
the cells also express both estrogen receptors (Figure IV-1), they offer a great tool to study 
estrogen’s impact on the hedgehog pathway. 
 
 All estrogens used, the pure agonist 17β-etradiol, the pure antagonist ICI 182,780, as well 
as the ERα specific agonist PPT, and the ERβ specific agonist DPN were able to inhibit Gli1 
mRNA in TRAMP-C2 cells (Figure IV-5). Estradiol was also able to inhibit Gli1 protein in 
TRAMP-C2 (Figure IV-6) and Gli-reporter activity in Shh Light II cells (Figure IV-8). This 
offers strong evidence for estrogenic regulation of hedgehog signaling and Gli1 expression. It is 
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thus possible that the phytoestrogens could be also working though the estrogen receptors to 
elicit its effect on the pathway. 
 
 Treatments with all seven botanicals were tried under a variety of conditions. In previous 
experiments with Shh Light II cells we were not able to obtain consistent stimulation with the N-
terminal Shh peptide, with stimulation varying between 3 and 8 fold between experiments. There 
were reports however, specifically from Dr. Beachy’s lab that reported 50-100 fold stimulation 
in the reporter activity. After adjusting our protocol (see materials and methods) we were able to 
obtain 20-40 fold stimulations with SAG and Shh-conditioned medium, however still not with 
the Shh peptide. Because of the variability and expense, we have stopped using the peptide. 
 
With these new conditions, the seven phytoestrogens did partially confirm previous 
results with the purified N-terminal Shh-peptide (Figure III-7 and IV-9). Apigenin had no or 
slightly stimulatory effects like previously observed, baicalein was now inhibitory with both 
SAG and CM, curcumin and resveratrol did inhibit, like they did with Shh, quercetin had no or 
slightly inhibitory effects like previously observed. Genistein had no significant effect, when I 
combined all results, which was due to significant differences between experiments, mainly we 
believe because slight differences in cell number caused significant changes in other confluency 
dependent pathways crosstalking with hedgehog signaling. Even though the Shh Light II cells 
were super-confluent at the time of treatment, and were incubated with the compounds for 
another 48 hours, a two-fold change in starting cell number made all the difference between 60% 
inhibition to 50% stimulation by genistein. The differences in variability might be suggesting 
different mechanisms these compounds might be working through.  
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EGCG was the most surprising compound with a very stable response regardless of cell 
density it had a stimulatory effect with SAG and a strongly inhibitory with Shh-conditioned 
medium. This differential response might shed light on its mechanism of action, specifically on 
the location of the estrogen receptor - if it is acting through ER. Shh and Shh-conditioned 
medium presumably too are acting directly through the Patched membrane receptor. SAG 
however is activating the pathway through direct binding to Smoothened, which is downstream 
of Patched. Thus the point of action of EGCG would be in between those two, potentially 
through a membrane associated estrogen receptor (Figure IV-10).  
 
We saw this discrepancy in inhibition pattern between CM- and SAG-stimulated activity 
again with high doses (1 and 10μM) of 17β-estradiol (Figure IV-8). The affinities for E2 in the 
membrane associated ER should not differ from the nuclear receptor. For the reported isoforms 
of ERβ, ERβ1, 2, and 5 are all expressed in the prostate and prostate cancer cells lines. ERβ5 has 
the lowest reported Kd of  ~25nM, and for ERβ2, which has additional 18 amino acids in the 
ligand binding domain binding has not been determined (344). A heterodimer between different 
isoforms might explain the discrepancy between binding affinities and responses observed. A 
previous graduate student in the Lubahn lab, Dr. Xiaohui Yuan, has found that ERβ binding 
affinities can differ as much as 50 fold between cell types. We now believe that these differences 
might be explained by different concentrations of oxysterols present in the different cell types, a 
hypothesis that is part of Sara Drenkhahn’s dissertation.  
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It was also surprising to see the ER antagonist ICI inhibit the hedgehog pathway just like 
estradiol did (Figure IV-5). However, in data from TRAMP-C2 and PC3M cells, in which 
neither E2 nor ICI alone, but a combination of both was able to inhibit prostate cancer cell 
growth (Figure II-5), we have reason to speculate that the effects of these are mediated by a 
membrane ER. Ellis Levin has published data suggesting that ERα and ERβ work as a 
heterodimer in the membrane (449). Thus perhaps ICI binds to one half of the heterodimer and 
estradiol bind to the other. 
ICI has been reported to bind and target nuclear ER for proteosomal degradation (22), but 
not membrane ER (Seminar S17-1 by Dr. PE Micevych at ENDO 2009) (450). Unpublished 
observations from Dr. Hannink’s lab suggested that ICI can also target ER to the plasma 
membrane. Thus it is possible that the synergistic effect of E2 with ICI could be explained 
through a two-step mechanism, in which ICI targets ER to the membrane, or enriches the 
membrane ER pool, and then E2 and the other botanicals can act upon it. 
 
A membrane ER, positioned between Patched and Smoothened, as the EGCG and high 
dose E2 data suggests, could be the missing link in explaining how Patched is able to inhibit 
Smoothened. The lack of protective effects of genistein in TRAMP mice in the absence of either 
receptor, as described in chapter II, is consistent with the idea that the membrane ER would have 
to function as an ERα/ERβ heterodimer (Figure IV-10). We also cannot exclude the 
involvement of other estrogen binding proteins like the G-protein coupled receptor 30 (GPR30), 
which has been reported to bind E2 and phytoestrogens in the micromolar range (451). Also, ICI 
will act as an agonist with GPR30 (452), or when the ER receptors are tethered to the AP-1 (453-
455), Sp1 (456, 457), and STAT5 (458) transcription factors in the nucleus.(459). 
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 Obviously, many additional questions have arisen that need following up in order 
to more clearly understand estrogen- and hedgehog-signaling crosstalk. Some of those questions 
will be discussed in the Future Studies, chapter V. 
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Figure IV-I: TRAMP-C2 and SHH Light II cells express both estrogen receptors. 
 
A ERα and ERβ mRNA in TRAMP-C2; B positive control: ERα mRNA in mouse uterus; ERβ 
mRNA in mouse ovary. ERα primers span exons 5-8, ERβ primers span exons 5-8 and 8-9. C 
Shh Light II cells express ERα mRNA, and low concentration of ERβ mRNA. 
 
ERα’s presence could be determined using primers spanning exons 2-3 (shown for Shh Light II 
only) and 5-8, and that of ERβ using primers spanning exons 5-8 and 8-9. Using the primer set 
spanning exons 5-8 we found that only one isoform of ERβ is present in the TRAMP-C2 cell line 
(NM 010157) which is missing exon 6, whereas 2 isoforms are present in the mouse ovary (NM 
010157 and NM 207707). 
 ERα     ERβ     ERβ 
A B 
 ERα     ERβ     ERβ 
 
 GAP   ERα  ERα  ERβ  ERβ 
C 
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Figure IV-2: Oxysterols as novel hedgehog pathway stimulators (307) 
 
Structures of 17β-estratiol, the newly described SERMs - 25- and 27-OHC (A), cyclopamine and 
cholesterol (B). This paper compared the structures of hedgehog-activating oxysterols to 
cyclopamine, suggesting that they would both bind Smoothened, and thus regulate the pathway. 
A different lab shortly thereafter demonstrated, that 20-, and 22-OHC were unable to displace 
cyclopamine from its binding site on Smoothened (411). 
27-hydroxycholesterol  25-hydroxycholesterol  
A 
B
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Figure IV-3: Selected oxysterols stimulate Gli1 mRNA in TRAMP-C2 cells. 
 
20-, 22-, 25-, and 27-OHC are able to stimulate Gli1 mRNA concentrations in TRAMP-C2 cells 
after a 24 hour treatment, as did the control compounds SAG and Shh. All treatments resulted in 
statistically significant stimulation.  
Each experiment was performed at least in triplicate. 
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Figure IV-4: Genistein inhibits stimulation by 25-, and 27OHC in TRAMP-C2 cells. 
 
TRAMP-C2 cells were treated for 24 hours with oxysterols +/- 50μM genistein. Both oxysterols 
are significantly stimulating Gli1 mRNA, and genistein is able to significantly inhibit, both the 
basal and stimulated state. 
Each experiment was performed at least in triplicate. 
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Figure IV-5: Estrogens and antiestrogens inhibit Gli1 mRNA in TRAMP-C2 cells. 
 
TRAMP-C2 cells were treated for 24 hours with selected compounds. * p<0.05, t-test. 
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Figure IV-6: E2 inhibits Gli1 protein in TRAMP-C2 cells. 
 
Representative western blot showing TRAMP-C2 cells treated for 24 hours with vehicle, SAG 
+/- cyclopamine and 10nM 17β-estradiol. E2 was able to significantly reduce Gli1 expression.  
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Figure IV-7: GliBS-reporter in TRAMP-C2 cells. 
 
TRAMP-C2 cells were transfected with GliBS-luciferase reporter and treated with various 
compounds. Surprisingly, the only compounds having significant effects on Gli activity were 25- 
and 27OHC, and those were both inhibiting. * p<0.05, t-test. 
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Figure IV-8: 17β-etradiol is significantly inhibiting SAG- and CM-stimulated Gli-reporter 
activity in Shh Light II cells. 
 
Shh Light II cells were treated for 48 hours with 100pM to 10μM E2 +/- SAG or Shh-
conditioned medium. E2 had no effects on baseline (data not shown) but did significantly inhibit 
stimulated GliBS-reporter activity. All treatments p < 0.05, t-test. 
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Figure IV-9: Botanical compounds with SAG and conditioned medium in Shh Light II 
cells.  
Each compound was tested at 10μM, except cyclopamine which was used at 1μM. 
 * p-value < 0.05, t-test 
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Figure IV-10: Working model of how botanicals might modulate hedgehog signaling 
pathway. 
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Chapter V - Future Studies 
 
While much has been accomplished over the course of my work, there are still questions 
that remain open, and new questions which arose as new data became available. Each of these 
questions might develop into a project by itself.  
From the genistein TRAMP studies with ERα- and ERβKO mice described in Chapter II, 
it is still left to rule out developmental consequences of missing estrogen receptors and their 
contribution to the protective vs. more PDC-prone genotype. Conditional KO mice, in which the 
gene for each estrogen receptor is turned off after completion of development, and preferably in 
the prostate only, would be ideal. The burden to breed triple transgenic mice to set up this study 
makes it undoable at this point. A possibly better solution would be the use of compounds 
selective for each receptor. At this point we have considered two compounds for our purposes 
that would, we hypothesize, recreate the results from our ERKO study, the ERα specific agonist 
PPT (propyl pyrazole triol) (460), and the ERβ specific agonist DPN (diarylpropionitrile). As 
mentioned before on of the problems with DPN is its low selectivity for ERβ over ERα, which is 
only about 70fold (461). Pilot-studies will be necessary to determine the optimal ER selective 
dosage. Another available compound to further distinguish between the dual roles of the 
receptors, specifically to answer the question whether ERα is the “driving force” for PDC, and is 
it required or necessary for PDC. This question could be answered by using the ERα antagonist 
MPP (methyl-piperidino-pyrazole) (462). And finally, as a proof of concept we could try to make 
the PDC incidence even higher by using the ERbeta-selective antagonist/ERalpha-agonist R,R-
THC (R,R-tetrahydrochrysene (463), or the metoxychlor metabolite 2,2-bis(p-hydroxyphenyl)-
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1,1,1-trichloroethane
 
(HPTE) which was previously shown to have selective agonist activity
 
through ERα and antagonist activity through ERβ and androgen receptor (AR) (464, 465).  
 
 To confirm that genistein is acting on prostate cancer in vivo, and specifically in vitro it is 
necessary to silence each receptor individually using siRNA or shRNA. If genistein is in fact 
requiring an ERα /ERβ heterodimer, knocking out either receptor would abolish its inhibitory 
effects, both on cell growth as well as on hedgehog signaling. 
 
 As far as genistein is concerned there are still other questions remaining. Genistein is 
showing slight stimulation of prostate cancer cell growth in vitro, at low concentrations, at 
100pM-1μM with PC3 (Figure III-9) and LNCaP (111) cells, but not in TRAMP-C2 or PC3M 
(Figure II-5), also been reported by others. But even though there is undisputable evidence that 
genistein has protective effects on low grade tumors (111) and disputable evidence about its 
protection againts PDC (356), it has been observed that genistein even though protective against 
primary tumors, induces metastasis to lymph nodes, both in immuno-compromised mice as well 
as in C57/Bl6 mice with orthotopic syngeneic tumors from RM-9 cells (466). Genistein has been 
also shown to promote neuro-endocrine differentiation in human prostate LNCaP cells, as 
demonstrated by increased expression of neuro-endocrine markers in genistein treatment-
surviving cells (467).  
All this could mean that cells that escape genistein inhibition are of more aggressive 
character, and therefore combination treatment is needed, with for example cyclopamine, or one 
of the cheaper botanical compounds described in this dissertation, like EGCG, which should 
target hedgehog signaling in aggressive metastasis-prone tumor cells, and with an estrogen 
receptor modulator, like MPP and/or DPN, to target ER’s protective effects. 
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To clearly demonstrate the need for one or both estrogen receptors in the inhibition of 
hedgehog signaling, we need to knock-down each receptor. siRNA studies targeted against ERα 
and ERβ are underway. From the differential responses with our botanical compounds in 
different assays it is apparent, that they are not necessarily working through the same 
mechanism. It is therefore necessary to test all of them without one or both estrogen receptors to 
confirm/exclude their inhibitory effects though the ER. 
A great natural and cheap tool that can be used to study the pre- and post- Smoothened 
hedgehog signaling is EGCG, which displayed strong inhibitory effects on Shh-conditioned 
medium-stimulated, but not SAG-stimulated hedgehog pathway activity. These effects need to 
be further tested in the prostate cancer cells, specifically PC3, PC3M and TRAMP-C2, with and 
without estrogen receptors present. 
Dose response with ICI, DPN and PPT should be completed, both in TRAMP-C2 and the 
Shh Light II cell line to have a full profile of their action to generate IC50 data and therefore 
correlations with their estrogenic activities and ER binding affinities. Also full dose responses 
are being performed by Sara Drenkhahn for the selected oxysterols, both with and without pre-
stimulation with SAG and Shh-conditioned medium. It would be interesting to test different cell 
lines for their oxysterol content, and see whether it correlated with their differential 
responsiveness to E2 and hedgehog. There is a whole new layer of combinations appearing, if we 
look at the synthesis of oxysterols. It has been proposed that mutations in the cholesterol 
pathway lead to perturbation of hedgehog signaling, due to decreased oxysterol pools. But now, 
the question arises, could both estrogen (468, 469) and androgen signaling in the prostate 
modulate cholesterol metabolism (470) and oxysterol production, which could modulate both 
hedgehog- and estrogen-signaling. 
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To answer the question about the roles of membrane ER in hedgehog signaling, it will be 
necessary to use impermeable E2, BSA or HRP linked, and assay short term responses to E2, 
ICI, and the selected botanicals, as well as hedgehog responses. Since the relative amount of 
membrane ER is small compared to nuclear fractions, it might be difficult to assay the changes in 
ICI induced membrane migration of ER. It would be really interesting to assay for the specific 
isoforms of ERα and ERβ, and their involvement in hedgehog responses.  
 
We have not discussed the thought of the involvement of the controversial membrane ER 
called GPR30 in our results. Does GPR30 interact with hedgehog signaling? Additionally, Ellis 
Levin has evidence for mitochondrial ER protein to be responsible for E2 response in breast 
cancer, he does not think it is GPR30.  
 
The interesting combinational effect with E2 + ICI also requires to be followed up upon, 
specifically to answer whether it has a similar synergistic effect on the hedgehog signaling 
pathway, both in the TRAMP-C2 and Shh Light II cells. It would be also good to conclude 
whether it involves membrane ERs.  
 
We cannot forget that the overall goal was to cure prostate cancer, all types of prostate 
cancer. With our current results, it seems that a combination treatment consisting of ER 
modulators and botanicals may potentially be useful in preventing and treating both types of 
cancer, WDC and PDC in the prostate, at least in the TRAMP. 
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Appendix - Spinach extracts in prostate cancer treatment 
 
Overview 
 
The main focus of our lab was to find novel botanical compounds, preferably with 
estrogenic properties that have been implicated in prostate cancer or cancer prevention and test 
them both, in our TRAMP mouse model as well as more recently in our hedgehog assays. Two 
of the compounds coming through the lab were spinacetin and patuletin, two flavones found in 
spinach, that had structural similarities with luteolin, a “legendary” compound acting through 
membrane ERs, but supposedly not nuclear ERs (Dr. Charlie Wang, personal communication). 
 
Dr. Lubahn obtained on a rather adventurous expedition to Spinach-country Fayetteville, 
Alma, AR large amounts of custom grown spinach. Dr. Rottinghaus’ lab to isolated the two 
candidate compounds from it – spinacetin and patuletin.  
 
We have subsequently tested these compounds in our lab, and found them to bind 
selectively to ERβ, but not ERα 66, 46, or 36, as originally expected. Both compounds were able 
to inhibit prostate cancer cell growth and showed promising results in our hedgehog assays, 
inhibiting Gli1 mRNA and the Gli-reporter. 
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Introduction 
We set out to find botanical compounds that would inhibit PDC in the TRAMP mice. To 
date all of our botanicals were able to decrease WDC incidence but had no effect on PDC. There 
were published reports that genistein (356), EGCG, green tea catechins (404) or green tea (403) 
and spinach extracts (471) were able to decrease PDC incidence in TRAMP mice. 
Our results do not confirm the effects of genistein in our TRAMP mouse system. EGCG 
was used in the drinking water in the described studies, we did not use EGCG alone, only in a 
dietary mix together with curcumin and resveratrol, and we did observe a 66% reduction in PDC 
incidence, which was not significant due to small animal numbers. Other labs saw reduction in 
PIN, but not PDC in TRAMP mice supplemented with EGCG (5). 
 
Neoxanthin, a compound present in Spinach leaf (Spinacia oleracea L.), has been found 
to have potent apoptotic and anti-prostate cancer cell activity in the low micro-molar range (472-
474). Spinach leaf (Spinacia oleracea) is a rich source of many flavonoids, carotenoids, 
neoxanthin, lutein, Vitamin C, and Vitamin E (471-473, 475). A water-soluble, natural 
antioxidant  extract (NAO) of spinach has been shown to slow the tumorigenic progression 
especially in high grade tumors (PDC) in TRAMP mice (471), prostatic carcinoma (472, 476, 
477) and liver (478) cell lines. NAO has been also shown to alleviate effects of 
oxidative/nitrosative damage in early neoplastic lesions in TRAMP mice (408). 
However, neoxanthin is rather unstable. Two flavones, patuletin and spinacetin (Figure 
V-1), found in high amounts in glucuronated forms in the spinach, are potentially the more likely 
contributors to spinach’s anticancer activity (479). We were additionally interested in these two 
flavones, due to their structural similarity to luteolin, an estrogenic compound (480-482)  with 
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interesting selectivity for estrogen receptors reported (483). Luteolin has been reported to inhibit 
angiogenesis (484, 485), growth of melanoma (486), and prostate cancer (487) cell lines. I 
decided to test the ability of luteolin, patuletin, and spinacetin to inhibit TRAMP-C2 and PC3 
growth and also their effects on hedgehog signaling. 
 
Materials and Methods: 
Spinach, spinacetin, patuletin 
Spinach was harvested, strains 380 and 415. Freeze dried spinach leaves were mixed with mQ 
autoclaved water in a 2:3 ratio, blended to obtain homogenous mixture, and double filtered 
through fast flow whatman filter paper. The yield was 65% for strain 380 and 45% for strain 415. 
Samples were given to Dr. Rottinghaus for further purification and isolation of patuletin and 
spinacetin. After first HPLC column purification, crude patuletin contained 49,000 ppm, 
spinacetin was 5,575 ppm, and was tested in protein, hedgehog, and binding assays at 0.1 and 
1%. After initial positive results in all assays, we received highly purified compounds. 
Luteolin was obtained from Sigma, St. Louis, MO.  
For Cell culture, real-time, and luciferase assays details see chapter IV.  
 
Results and discussion 
Both spinach compounds, patuletin and spinacetin, were able to inhibit mouse prostate 
cancer cell growth, as well as hedgehog signaling as measured by a decrease in Gli1 mRNA 
concentrations (Figure V-2). In an independent assay Sara Drenkhahn was testing both 
compounds for inhibition of Shh-stimulated Gli-reporter in Shh Light II cells (Figure V-3). In all 
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assays, patuletin was the more potent compound, with 300nM patuletin and 1μM spinacetin 
significantly inhibiting Gli1 mRNA in TRMAP-C2 cells.  
 
From the results of our ERα- and ERβKO we would expect an ERβ agonist to prevent 
PDC incidence, luteolin was supposed to act primarily through ERβ (488). We therefore 
expected that the structurally similar patuletin and spinacetin would be ERβ-selective as well, 
and the cancer protective actions of spinach could be attributed to the estrogenic activity of those 
compounds.  
 
Nick Starkey in our lab, was able to confirm ERβ-selectivity of luteolin, and was able to 
demonstrate binding to ERβ at nanomolar concentrations, compared with micromolar affinites to 
ERα (data not shown). 
 
Since both compounds were able to inhibit prostate cancer cell growth, as well as inhibit 
Hedgehog signaling as determined by decreased Gli1 mRNA in TRAMP-C2 cells, and decreased 
Gli-reporter activity in Shh Light II cells (work done by Sara Drenkhahn), we set out to test 
spinach extracts in vivo in our TRAMP mice.  
The results of our mouse studies were very surprising. The PDC incidence in the 
FVB/C57 mice was significantly higher in the control group than expected - 41%, compared to 
19% in pure C57B6, and 30% from previous FVB/C57 wheat diet studies. Although the PDC 
incidence in the ERβKO mice was comparable to previous results with pure C57 TRAMP mice, 
48% and 41% respectively, we did not observe an increase in PDC due to the high baseline in the 
control group. Whole dried spinach extracts at 0.2 and 2% showed slight although not quite 
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statistically significant protection in WDC incidence in the WT animals, but an increased WDC 
incidence in the KOs (again, not statistically significant). There were no statistically significant 
effects in the PDC incidence, but trends suggested increased PDC incidence in the WTs, and 
protection in the KOs. 
These results are slightly discouraging, but do not exclude potential protective effects 
from purified spinach extracts like patuletin and spinacetin. It would be still useful to test these 
two compounds, possibly in a TRAMP-C2/TRAMP isograft model, or a xenograft model for 
hedgehog inhibiting and prostate cancer treatment potential.
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Figure A-I: Flavonoids in spinach (479) and luteolin.
 
luteolin 
 139 
 
 
 
 
 
 
Figure A-2: Patuletin and Spinacetin inhibit cell growth and Gli1 in TRAMP-C2 cells. 
 
Crude 0.1% patuletin and spinacetin inhibit total cellular protein (A) and Gli1 mRNA (B) after a 
72 hour treatment of TRAMP-C2 cells. (C) Highly purified patuletin and spinacetin inhibit Gli1 
mRNA less potent than the crude extract. 
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Figure A-3: Patuletin and Spinacetin inhibit GliBS reporter activity in SHH Light II cells 
(done by Sara Drenkhahn). 
 
SHH Light II cells were treated for 24 hours with cyclopamine, patuletin, and spinacetin +/- N-
Shh peptide, before being lysed, and assayed for luciferase activity. * p<0.05  
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Figure A-4: Luteolin inhibits prostate cancer cell growth in vitro. 
 
Luteolin inhibits TAMP-C2 (A) and PC3 (B) cell growth as measured by total protein after a 72 
hours treatment. 
A B 
IC50 = 5μM  IC50 = 30μM  
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Control Diet HYP PIN WDC PDC 
 WT 0/27 1/27 15/27 11/27 
  KO 0/25 5/25 8/25 12/25 
      
0.2% Diet      
 WT 0/23 5/23 7/23 11/23 
  KO 0/23 3/23 11/23 9/23 
      
2% Diet      
 WT 0/27 4/27 8/27 15/27 
 KO 0/23 2/23 13/23 8/23 
  
 
 
 
Control Diet HYP PIN WDC PDC 
 WT 0% 4% 55% 41% 
  KO 0% 20% 32% 48% 
      
0.2% Diet      
 WT 0% 22% 30% 48% 
  KO 0% 13% 48% 39% 
      
2% Diet      
 WT 0% 15% 30% 55% 
 KO 0% 9% 57% 35% 
 
 
 
Table A-1: Preliminary results from TRAMP spinach study (done by Dr. Glenn Jackson). 
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